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Abstract 
 
Methylphenidate (MPH) is a first-line stimulant drug available worldwide to treat 
attention deficit hyperactivity disorder (ADHD). ADHD is one of the most prevalent 
neuropsychiatry disorders in children and adolescents. Despite the already proven 
therapeutic efficiency, concerns have been raised regarding the possible consequences of 
MPH exposure during childhood and adolescence. Previous animal studies have focused 
on MPH’s possible neurotoxicity but many do not correlate to the clinical use of MPH 
since high doses are administrated via intraperitoneal or intravenous route. Moreover, 
MPH effects on the peripheral organs have been scarcely studied.  
This dissertation aimed to evaluate the MPH effects to the brain and peripheral 
organs of adolescent rats using an oral dose scheme that mimics the therapeutic doses 
administered to human adolescents. 
Adolescent male Wistar rats (postnatal day 40) received two doses of MPH (5 
mg/kg in a 5% sucrose solution), orally, 5 hours apart, for seven days, while controls 
received equal volume of 5% sucrose using the same scheme. Body temperature, weight 
and food/water intake were measured daily. Twenty-four hours after the last 
administration, rats were sacrificed and brain areas [cerebellum, prefrontal cortex (PFC), 
hippocampus, and striatum], peripheral organs (liver, heart, and kidneys), and blood were 
collected for posterior analysis. The body temperature, weight gain and food/water 
consumption were similar between controls and MPH-treated animals. In the brain, MPH 
significantly increased the reduced glutathione/oxidized glutathione (GSH/GSSG) ratio in 
the PFC and hippocampus. However, quinoprotein levels were significantly increased in 
the cerebellum of MPH-treated rats. No significant changes were found in adenosine 
triphosphate (ATP) or protein carbonylation levels after the MPH treatment in any 
evaluated brain area. In the peripheral organs, no differences were found regarding ATP, 
quinoprotein, or protein carbonylation levels. However, the GSH/GSSG ratio was 
significantly increased in the heart of MPH-treated rats. The histological examination of 
MPH-treated rat hearts revealed significant damage, namely interstitial edema, vascular 
congestion, and presence of fibrin-like material. In the kidneys, necrotic areas with cellular 
disorganization and cell infiltration were found following MPH treatment. The lack of 
severe cellular damage and/or necrosis in the liver or heart of MPH-treated rats was 
corroborated by the absence of changes in the plasma levels of several markers (alanine 
aminotransferase, aspartate aminotransferase, creatine-kinase MB, and total creatine 
kinase). Furthermore, the amount of fibrous tissue was assessed by the Picrosirius Red 
staining and no differences were found among groups. 
 xiv 
 
Altogether, these results suggest that one-week exposure to pharmacological 
relevant oral doses of MPH protected the PFC, hippocampus, and the heart from oxidative 
stress but, on the other hand, compromised the normal tissue organization of the heart 
and kidneys. Thus, further investigation is needed to discover the underlying mechanisms 
of these changes on adolescent animals, especially because a lifetime administration or a 
prolonged exposure of MPH is required in ADHD treatment. 
 
Keywords: methylphenidate, adolescent rat, brain, peripheral organs, histology, toxicity. 
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Resumo 
 
O metilfenidato (MPH) é um estimulante usado como primeira escolha terapêutica 
em todo o mundo para o tratamento da perturbação de hiperatividade/défice de atenção 
(PHDA). A PHDA é uma das perturbações neuropsiquiátricas mais prevalentes em 
crianças e adolescentes. Apesar da comprovada eficácia terapêutica, têm sido 
levantadas questões relativamente às possíveis consequências da exposição ao MPH 
durante a infância e a adolescência. Os estudos em animais têm-se centrado na possível 
neurotoxicidade deste fármaco, mas muitos investigadores usam doses elevadas 
administradas via intraperitoneal ou intravenosa que não se relacionam com o uso clínico 
do MPH. Além disso, os efeitos do MPH nos órgãos periféricos têm sido pouco 
estudados.  
Esta dissertação teve como objetivo avaliar os efeitos do MPH no cérebro e nos 
órgãos periféricos em ratos adolescentes após um protocolo experimental que imita o 
regime terapêutico oral adotado em humanos adolescentes. 
 Ratos Wistar machos adolescentes (40 dias de idade) receberam duas doses de 
MPH (5 mg/kg dissolvidos numa solução de sacarose a 5%), via oral, com cinco horas de 
intervalo, durante sete dias, enquanto os controlos receberam um volume igual de 
sacarose a 5% no mesmo esquema. A temperatura corporal, o peso, a ingestão de água 
e o consumo de alimentos foram medidos diariamente. Vinte e quatro horas após a última 
administração, os ratos foram sacrificados e as áreas cerebrais [cerebelo, córtex pré-
frontal (PFC), hipocampo e estriado], os órgãos periféricos (fígado, coração e rins) e o 
sangue foram recolhidos para posterior análise. A temperatura corporal, o peso, a 
ingestão de água e o consumo de alimentos foram semelhantes entre os controlos e os 
animais tratados com MPH. No cérebro, o MPH aumentou significativamente o rácio 
glutationa reduzida/glutationa oxidada (GSH/GSSG) no PFC e no hipocampo. No entanto, 
houve um aumento significativo dos níveis de quinoproteínas no cerebelo dos ratos 
tratados com MPH. Não foram encontradas diferenças no que diz respeito aos níveis de 
adenosina trifosfato (ATP) e de carbonilação proteica em todas as áreas cerebrais em 
comparação com o controlo. Nos órgãos periféricos, não foram observadas diferenças 
nos níveis de ATP, quinoproteínas e carbonilação proteica entre grupos. No entanto, o 
rácio GSH/GSSG aumentou significativamente no coração dos ratos tratados com MPH. 
A observação histológica do coração revelou danos significativos, nomeadamente edema 
intersticial, congestão vascular e a presença de um material semelhante à fibrina. Nos 
rins, foram encontradas áreas necróticas, desorganização celular e infiltração celular 
após o tratamento com MPH. A ausência de dano celular grave e/ou necrose no fígado e 
 xvi 
 
no coração dos ratos tratados com MPH foi corroborada pela ausência de diferenças nos 
níveis plasmáticos de vários marcadores (alanina aminotransferase, aspartato 
aminotransferase, creatina quinase MB e creatina quinase total). Além disso, a 
quantidade de tecido fibroso foi avaliada pela coloração “Picrosirius Red” e não foram 
encontradas diferenças nos órgãos entre os animais controlos e tratados. 
 Analisando todos os resultados, estes parecem sugerir que um tratamento de uma 
semana com doses orais de MPH farmacologicamente relevantes protegem o PFC, o 
hipocampo e o coração contra o stress oxidativo mas, por outro lado, compromete a 
organização morfológica do coração e rins. Assim, mais estudos em animais 
adolescentes são necessários para avaliar os mecanismos subjacentes às alterações 
encontradas especialmente porque, no tratamento da PHDA, o MPH é administrado 
durante longos períodos ou durante toda a vida. 
 
Palavras-chave: metilfenidato, ratos adolescentes, cérebro, órgãos periféricos, histologia, 
toxicidade. 
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1. Introduction 
 
1.1. Attention Deficit Hyperactivity Disorder (ADHD) 
 
Attention deficit hyperactivity disorder (ADHD) is particularly relevant nowadays 
since it is one of the most common neuropsychiatric disorders in school-aged children and 
adolescents (Matthews et al., 2014). Although this complex disorder is presently known by 
the impulsivity and/or inattention and hyperactivity, the clinical characterization and 
conceptualization of ADHD suffered alterations over the last 200 years (Lange et al., 
2010, APA, 2013, Matthews et al., 2014). 
The first example of a disorder that resembled ADHD was described in 1798, when 
Crichton defined attention, and distinguished the abnormal inattention observed in 
children with school learning difficulties (Lange et al., 2010). However, it was in 1902 that 
George Still first described ADHD in his series of three published lectures to the Royal 
College of Physicians (Still, 1902). 
Over the years, the clinicians eventually adopted different terms like “minimal brain 
dysfunction” (Clements, 1966), “hyperkinetic reaction of childhood” (APA, 1968), and 
“attention deficit disorder with or without hyperactivity” (APA, 1980) to describe the 
symptoms of ADHD. In 1987, the disorder was finally renamed “attention deficit 
hyperactivity disorder” in the Diagnostic and Statistical Manual of Mental Disorders (DSM), 
third revised edition and all three key features of ADHD (impulsivity, inattention, and 
hyperactivity) were specified (APA, 1987). 
The fourth edition of DSM published in 1994 brought the distinction between two, 
yet correlated, domains of behavior: a set of symptoms for inattention and a set of 
symptoms for hyperactive/impulse behavior that allowed the diagnosis of three subtypes 
of ADHD: predominantly inattentive, predominantly hyperactive/impulsive, and a 
combined type, according to a list of criteria established by that manual (APA, 1994). 
The latest characterization of the disorder is present in the DSM fifth edition. 
According to this edition, ADHD is described as “a persistent pattern of inattention and/or 
hyperactivity-impulsivity that interferes with development, has symptoms presenting in two 
or more settings (e.g. at home, school, or work), and negatively impacts directly on social, 
academic or occupational functioning” (APA, 2013). The description is followed by the 
guidelines used to correctly diagnose a particular ADHD subtype: symptoms must have 
onset before the age of 12 and children must exhibit at least 6 symptoms from the 
inattention group (e.g. easily distracted, poor concentration, difficulty completing tasks), 
from the hyperactivity/impulsivity (e.g. difficulty waiting and remaining seated, talk 
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excessively) or both for at least 6 months (APA, 2013, Sharma and Couture, 2014). The 
main difference of this edition when compared with the previous editions is the 
acknowledgement of a persistent ADHD throughout the patient’s life. ADHD prevalence in 
children and adolescents ranging from 4 to 17 years old is presently 5% worldwide (APA, 
2013). Although symptoms may decrease with age, in some cases, they can persist and 
the prevalence rate in adulthood is estimated at approximately 2.5% (Polanczyk et al., 
2007, Simon et al., 2009, Geissler and Lesch, 2011, APA, 2013, Matthews et al., 2014). 
For a reliable diagnosis, older adolescents and adults over 17 years only need to display 5 
of the previously stipulated symptoms (APA, 2013, Sharma and Couture, 2014). 
Comorbidities like anxiety disorders, oppositional defiant disorder, and major 
depressive disorder can lead to a misdiagnosis of ADHD since they have symptoms and 
characteristics very similar to ADHD. Thus, the ADHD diagnosis is a complex and a 
challenging process done not only by clinicians after repeated observations, but also by 
using reports obtained from parents, teachers or other caregivers (Sharma and Couture, 
2014). 
 
1.1.1. Etiology and pathophysiology  
 
As previously stated, the etiology and pathophysiology of ADHD is complex and far 
from being completely understood. Advances in current technology allowed a more 
focused research based in neuroimaging, neurochemistry, and genetics and, so far, it is 
known that environmental factors may have an important role on ADHD development. 
However, it is believed, at this point, that genetics gives a strong contribution to this 
disorder (Cortese, 2012, Bruxel et al., 2014). 
 
1.1.1.1. Neuroimaging studies 
 
Differences in brain structure in children with ADHD versus children without ADHD 
were detected by neuroimaging techniques, like magnetic resonance imaging (MRI). A 
reduced global brain volume, most prominent in the splenium of the corpus callosum, the 
right caudate and the total and right cerebral volume (Castellanos et al., 2002, Valera et 
al., 2007) and a reduced global grey matter volume, most prominent in the right lentiform 
nucleus and extending to the caudate were some of the abnormalities observed through 
imaging (Nakao et al., 2011). Global thinning of the cortex has also been reported. In a 
study with 166 children with ADHD, Shaw and co-workers concluded that the ADHD group 
had a significantly smaller cortical thickness, especially in the medial and superior 
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prefrontal and precentral regions (Shaw et al., 2006). A work of the same team also 
referred a significant delayed cortical maturation in the middle prefrontal cortex (PFC), 
after a study conducted with 223 children and adolescents with ADHD based in peak 
cortical thickness (Shaw et al., 2007). 
Structural brain connectivity is also affected in children and adult with ADHD. 
Through diffusor tensor imaging, disruptions in white matter integrity, mainly in the fronto-
striatal circuitry, have been reported (Weyandt et al., 2013). 
The anatomic brain changes seen in ADHD results in functional alterations. The 
activation of neural systems measured by functional MRI (fMRI) during two tasks involving 
executive control (“stop” task and “delay” task) showed a lower brain activity in the 
prefrontal systems in adolescents (12 to 18 years old) with ADHD versus control subjects 
(Rubia et al., 1999). Similarly, by measuring the activity of neural regions across time 
through task-related studies, fMRI has shown hypoactivation (i.e. reduced blood flow) in 
the frontoparietal and ventral attentional networks, while hyperactivation in the default 
networks occurred in both children and adults with ADHD (Cortese, 2012, Cortese et al., 
2012).  
Overall, these findings point to a frontal-striatum-cerebellum disorder that 
encompass regions related to attention, cognition, sensorimotor functions, and emotions 
(Cortese, 2012, Bruxel et al., 2014). 
 
1.1.1.2. Molecular and genetics studies 
 
Taking into consideration the multiple symptoms of ADHD, several altered brain 
structures have arisen as potential culprits of ADHD. However, none of the changes found 
explains by itself the etiology of ADHD, thus several theories persist at this point. 
Regarding neurotransmitter alterations, deficits in dopamine (DA) and 
noradrenaline (NA) were observed by positron emission tomography (PET) studies and 
they seem involved in the pathophysiology of ADHD. Both catecholamines are involved in 
the control of multiple neural systems, like locomotion, cognition, working memory, 
arousal, and vigilance (Prince, 2008). Additionally, it is well established that DA and NA 
play a critical role in the PFC, a brain region with structural and functional lesions already 
reported in subjects with ADHD (Rubia et al., 1999, Shaw et al., 2007). The PFC network 
activity is fragile and extremely sensitive to small changes in catecholamine 
concentrations, thus, either insufficient or excessive DA and/or NA can affect the 
executive functions of PFC and influence some behaviors like poor attention, impulsivity 
and hyperactivity (Arnsten et al., 2009, Arnsten and Pliszka, 2011). It is hypothesized that 
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when too little DA/NA is released from presynaptic neurons, there is an insufficient 
activation of postsynaptic receptors D1/α 2A, respectively, which can lead to distraction and 
impulsivity. On the other hand, when excessive DA/NA is released, there is 
overstimulation of the α1, β1, D1 and possible D4 receptors in postsynaptic neurons and the 
individual shows inattention (Sharma and Couture, 2014). 
Besides neurotransmitter alterations, molecular genetic studies also imply several 
genes related with the catecholaminergic system in the pathophysiology of ADHD 
(Cortese, 2012). 
The gene that encodes dopamine transporters (DAT) protein 1 (DAT1) has been 
largely focused on ADHD related investigation. DAT are mainly distributed in the striatum 
and nucleus accumbens and they are responsible for regulating dopaminergic 
neurotransmission. Additionally, DAT are also targets for methylphenidate (MPH) and 
amphetamine (AMPH), two drugs used to treat ADHD. DAT inhibition leads to an increase 
of the neuronal signal and synaptic DA levels and the attenuation of the symptoms 
(Prince, 2008, Faraone et al., 2014). Therefore, DAT1 has been a central role in ADHD 
etiology and pathophysiology.  
Two DA receptor genes seem also strongly related with ADHD pathophysiology. 
DA receptor gene 4 belongs to the D2 class of the DA receptors and it is highly expressed 
on frontal lobe regions, which are associated with attention and inhibition behavior. DA 
receptor gene 5 belongs to the D1 class of DA receptors and it is implicated in 
hippocampal memory formation (Gizer et al., 2009, Faraone et al., 2014). 
Another candidate gene that might be associated with ADHD is a functional 
polymorphism of the serotonin transporter (5-HTT) gene, which has a long and a short 
variant related with a faster or slower serotonin (5-HT) reuptake and a subsequent 
decrease or increase in the levels of active 5-HT, respectively. The genetic polymorphism 
linked to this transporter might play an important role since the 5-HTT gene is expressed 
in neural systems related to attention, memory, and motor activities (Gizer et al., 2009). 
Also related to 5-HT is the 5-HT1B receptor. An increased aggression and impulsive 
behavior in knockout mice for this receptor (Brunner and Hen, 1997) caught the attention 
to this gene, and a significant association to the pathophysiology of ADHD has been 
reported (Gizer et al., 2009). 
Other authors started to consider new genes as potential disruption structures in 
ADHD, namely the synaptosomal-associated protein 25 (SNAP25). SNAP25 is a plasma 
membrane protein essential for synaptic vesicle fusion and neurotransmitter release and it 
is also involved in synaptic plasticity and axonal growth. A hyperactive phenotype similar 
to ADHD is present in the coloboma mouse strain lacking one copy of the SNAP25 gene 
(Brophy et al., 2002, Gizer et al., 2009). 
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Altered proteins, like the ones that resulted from genes like DA receptor gene 3, 
dopamine beta hydroxylase, catechol-O-methyltransferase, α2A adrenergic receptors and 
brain derived neurotrophic factor also seem related with ADHD but, so far, the results do 
not clearly point their specific role on the disorder (Gizer et al., 2009, Bruxel et al., 2014). 
The role of genes in the etiology of ADHD has been also corroborated in humans, 
mainly family studies. Family studies showed a 2 – 8 fold increase risk of ADHD in 
children from parents that presented the disorder. A higher rate of symptoms in biological 
relatives when compared with adopted ones was also observed in adoption family studies. 
However, studies with twins show the most compelling data to prove the heritability of the 
disorder (Faraone et al., 2005, Mick and Faraone, 2008). Faraone and co-workers 
estimated a mean heritability equal to 76% after a review of 20 twin studies from Australia, 
the European Union, Scandinavia, and the United States, giving to ADHD the title of the 
most heritable psychiatric disorder (Faraone et al., 2005). Therefore, most studies that 
search for the putative changed targets responsible for ADHD are genetic studies. 
Even so, ADHD heritability is lower than 100%, therefore environment factors must 
bear some influence in the etiology of ADHD. Prematurity/low birth weight, prenatal 
smoking, exposure to cocaine, alcohol or lead, and diet (i.e. nutritional deficiencies) are 
some of the environmental factors considered at this point. The two environmental factors 
that were shown a substantial body of evidence are prematurity/low birth weight and 
prenatal smoking with a, respectively, 2.64 and 2.39 fold increased risk for developing 
ADHD (Cortese, 2012, Tarver et al., 2014). 
Although the majority of the research is focused on molecular genetic studies with 
ADHD, methodological and technical limitations make it extremely difficult to identify the 
exact genes, so, both gene-gene interactions and genome-wide association studies have 
emerged in pharmacogenetics trying to establish concrete associations between genes 
and the ADHD disorder (Cortese, 2012, Bruxel et al., 2014). In fact, some of the 
environmental factors can trigger genes susceptible to ADHD that, otherwise, would be 
silent. Therefore, gene-environment interactions can result in the increased likelihood to 
manifest this disorder. So far, some studies have already found interactions between 
dopaminergic genes and prenatal smoking and/or alcohol intake but further investigation 
is needed to replicate results and identify potential mechanisms (Nigg et al., 2010, 
Cortese, 2012).  
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1.1.2. Present pharmacological treatment of ADHD 
 
Pharmacological treatment of ADHD is an important piece to understand the 
pathophysiology of the disorder. In fact, medication is usually used to interact directly with 
the catecholaminergic system, more specifically with DA and NA pathways. As mentioned 
above, both catecholamines interact with the PFC, which has massive connections to the 
caudate, cerebellum, motor, and sensory cortices and regulates attention, behavior, and 
emotions (Arnsten and Li, 2005, Arnsten and Pliszka, 2011). Since impairment of 
catecholamine levels in PFC influence behaviors like poor attention, impulsivity, and 
hyperactivity, drug therapy aims to obtain the optimal level of DA and NA for the PFC 
proper function and, by that, eliminate those typical symptoms of ADHD (Arnsten et al., 
2009).  
According to the Food and Drug Administration (FDA), there are both stimulant 
and non-stimulant options for pharmacological treatment of ADHD (Swanson and Volkow, 
2002). Stimulants are considered first-line agents and include MPH and AMPH, which are 
considered equally effective with a wide margin of safety for long-term treatment (Sharma 
and Couture, 2014). In general, they act at the DAT and the NA transporters (NAT) given 
the similar chemical structure to DA and NA, as both drugs and catecholamines present 
the phenylethylamine moiety (Figure 1). However, neurochemical effects and mechanisms 
of action are distinct (Arnsten and Pliszka, 2011). Briefly, AMPH binds to DAT, NAT, and 
5-HTT and leads to the release of the monoamines from presynaptic terminals, which 
produces a massive increase in the neurotransmitters at the synaptic cleft (Teixeira-
Gomes et al., 2015). Additionally, AMPH can be transported into intraneuronal storage 
vesicles and deplete the monoamine content of the vesicles, since it has affinity for 
vesicular monoamine transporter 2 (VMAT-2) (Carvalho et al., 2012, Teixeira-Gomes et 
al., 2015). Lastly, AMPH is also a reversible inhibitor of monoamine oxidase, so, once 
inside the presynaptic terminals, it can decrease the levels of monoamines metabolites 
like the DA metabolite (dihydroxiphenylacetic acid – DOPAC) and augment the synaptic 
levels of the monoamine neurotransmitter (Teixeira-Gomes et al., 2015). Although AMPH 
acts at DAT, NAT, and 5-HTT, the main mechanism of action is on DAT. That action on 
DAT ultimately results on a major release of DA from the presynaptic nerve terminals 
(Teixeira-Gomes et al., 2015). Meanwhile, MPH acts as a pure inhibitor of DAT, not as a 
substrate like AMPH, but this will be further detailed in section 1.2.. 
Although stimulants are proven safe and efficient, they are not adequate for nearly 
30% of ADHD patients (Spencer et al., 1996). Several reasons like nonresponsiveness or 
partial responsiveness to stimulants, intolerance to their side effects (i.e., insomnia, 
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anorexia, irritability, nausea, headache, anxiety), presence of medical issues such as tic 
disorders and/or any cardiac structural abnormalities, cardiomyopathy or abnormalities of 
the heart rhythm, and the potential abuse or dependence are point out as reasons for the 
therapeutic failure for ADHD treatment (Wolraich and Doffing, 2004, Budur et al., 2005, 
Sharma and Couture, 2014). 
MPH pharmacological and adverse effects will be more deeply aproached in a 
subsequent section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Chemical structures of MPH, AMPH, and of the neurotransmitters NA and DA. 
 
In 2002, the first non-stimulant drug, atomoxetine, was approved by FDA (Chai et 
al., 2012). Atomoxetine is a selective NAT inhibitor and it is capable to increase levels of 
both DA and NA in the PFC and improve PFC function (Bymaster et al., 2002, Sharma 
and Couture, 2014). Despite being considered for some authors a first-line treatment for 
patients with comorbid anxiety or active substance abuse disorder (Leuchter et al., 2014), 
FDA advises against rare cases of hepatotoxicity after its consumption (Sharma and 
Couture, 2014). This non-stimulant is metabolized via cytochrome P450 (CYP) 2D6 in the 
liver and the genetic polymorphisms in this isoenzyme can be a concern in some 
susceptible patients (Bolea-Alamanac et al., 2014). 
Moreover, α2 agonists can also be a therapeutic alternative for the treatment of 
ADHD symptoms. NA receptors are classified as α1 (α1A, α1B, α1D), α2 (α2A, α2B, α2C) and 
β1, β2 and β3 receptors and it is known that NA has highest affinity for the α2 receptor 
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family (Arnsten, 2010, Sharma and Couture, 2014). The α 2A subtype is the most 
predominant adrenergic receptor type in PFC and a disruption in this receptor or in its 
distribution can lead to impaired attention, poor impulse control, and hyperactivity. 
Therefore, it has been postulated that the use of α2 agonists like clonidine and guanfacine 
can mimic NA actions on the postsynaptic receptors and control the deviant behaviors 
(Arnsten and Pliszka, 2011). In fact, both clonidine and guanfacine are presently used in 
children and adolescents aged 6–17 years in monotherapy or as adjunctive therapy when 
the stimulant does not fully treats the ADHD symptoms (Gormley et al., 2014). 
A formulation of guanfacine extended release (ER) was approved in 2009 by the 
FDA (Laughren, 2009). Guanfacine, as stated, is a postsynaptic α2 adrenergic receptor 
agonist that acts preferentially at α2A receptors, thus, strengthening the PFC network 
connections. Compared to clonidine, guanfacine has 10 times less affinity for the 
presynaptic α 2A adrenoceptors, therefore, has lower rates of sedation (Dopheide and 
Pliszka, 2009, Bidwell et al., 2011). 
Clonidine was first approved as an antihypertensive medication but, in 2010, the 
ER formulation of the drug was approved, by FDA, for the treatment of ADHD (FDA, 
2010). It stimulates both pre- and postsynaptic α2A receptors and has high affinity for all 
three subtypes of α2 receptors and for imidazoline I1 receptors, whose stimulation may 
mediate many of the hypotensive effects of this drug (Bidwell et al., 2011). 
When both stimulant and non-stimulant drugs described above do not result in 
symptoms improvement, a third-line medication can be considered, that include bupropion 
and tricyclic antidepressants (Bolea-Alamanac et al., 2014). Bupropion is an FDA-
approved drug for the treatment of depressive disorder and nicotine dependence but, it 
has also been used as an off-label drug to treat ADHD because it is a DA and NA 
reuptake inhibitor (Maneeton et al., 2014). This drug shows some advantages over MPH 
and AMPH, because it has a lower risk for abuse potential. Moreover, bupropion has a 
faster onset of action when compared with atomoxetine or α2 agonists (Maneeton et al., 
2014, Sharma and Couture, 2014). However, bupropion has a worst side effect profile and 
is associated with dose-related risk of seizures (Sharma and Couture, 2014). Tricyclic 
antidepressants have a well-demonstrated efficacy in treating impulsive and hyperactive 
behaviors thanks to their noradrenergic properties, but they are not so effective like 
stimulant drugs. Although they have some advantages over stimulants, like no risk of 
abuse potential and the ability to overcome depression and tics, they are third line 
medications because of their large number of side effects, namely sedation and life 
threatening overdose (Popper, 1997, Sharma and Couture, 2014). 
A considerable inter-individual variability among patients implies a gradual dosage 
titration and a trial-and-error approach to allow the monitoring of the response to 
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medication, dosing, and adverse effects (Bruxel et al., 2014). Moreover, pharmacological 
treatments should be combined with non-pharmacological treatments as part of a 
comprehensive treatment plan that may include behavioral therapy, psychoeducation, 
lifestyle changes and diet. These approaches should include not only the patients but also 
their families and teachers (Tarver et al., 2014). 
In the next sections, the stimulant MPH used for ADHD treatment will be 
addressed, since this will be the drug studied in this thesis.  
 
1.2. Methylphenidate (MPH) 
 
This drug was first synthesized in 1944 and it was initially indicated for chronic 
fatigue, depressive states, psychosis associated with depression, among others. 
Nowadays, it is considered the primary stimulant used to treat ADHD symptoms for its 
nanomolar affinity for DAT and NAT (Leonard et al., 2004, Madras et al., 2005). 
MPH is a piperidine-derived molecule that contains two chiral centers and exists as 
four isomers, i. e., d-threo, l-threo, d-erythro and l-erythro-MPH. Originally, MPH was 
marketed as a mixture of all four isomers (80: 20 racemic erythro and threo-MPH) but 
subsequent investigation of the separated racemates soon eliminated the eryhtro of the 
pair, since it did not have any major activity in the central nervous system (CNS) 
(Challman and Lipsky, 2000, Leonard et al., 2004). Nowadays, the drug is marketed as 
the racemic mixture of the threo pair (50:50) (Heal and Pierce, 2006). Additionally, studies 
have shown that the d-isomer is the major responsible for the pharmacological activity 
once it is approximately 10 fold more potent than the l-isomer in the inhibition of DAT and 
NAT. Therefore, pure formulations of d-threo-MPH (dexmethylphenidate) have also been 
used since it has similar properties of the racemic mixture, but it is twice more potent 
(Challman and Lipsky, 2000, Wolraich and Doffing, 2004, Heal and Pierce, 2006).  
Regarding the prescription of this drug, the usual daily oral dose of an immediate 
release (IR) formulation ranges from 10 to 60 mg (Barceloux, 2012). Along with IR 
formulations, which imply repeated administrations during the day, intermediate- and long-
acting formulations are also prescribed. The routes of administration of these preparations 
are essentially two: oral or transdermal (patch in the skin) (Kaplan and Newcorn, 2011, 
Sugrue et al., 2014). The main features of each MPH preparation are presented in Table 
1. 
In the brain, more specifically in the striatum where DAT density is higher, MPH 
binds to the neuronal DAT and inhibits the reuptake of DA from the synaptic cleft (Volz, 
2008). Usually, DAT allows the decrease in the synaptic cleft of the DA released by the 
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pre-synaptic neuron so, MPH by inhibiting this transporter, increases DA concentrations in 
the synaptic and extracellular space leading to a prolonged and/or intensified DA 
postsynaptic signal (Madras et al., 2005, Volz, 2008). 
MPH also affects the vesicular monoamine transporter 2 (VMAT-2). In the CNS, 
VMAT-2 controls biogenic amines storage and it uptakes cytoplasmic DA into the synaptic 
vesicles to avoid oxidative deamination of the monoamine in the cytoplasm. A single 
administration of MPH redistributes VMAT-2 within nerve terminals from the synaptosomal 
membranes to the cytoplasm, which promotes sequestration of DA into the vesicles, 
therefore increasing the DA content available for vesicular release (Sandoval et al., 2002, 
Zheng et al., 2006).  
Although MPH blocks more than 60% of DAT activity at oral therapeutic doses 
(0.3-0.6 mg/kg), it exhibits a large interindividual variability in the magnitude of increase of 
extracellular DA. This could be explained both by the blockade of DAT and the rate of DA 
release, which is regulated by individual differences in DA cell firing and by environmental 
stimulation (Pucak and Grace, 1994, Volkow et al., 2005). 
Most of the ADHD research focused on dopaminergic system, but it is known that 
ADHD involves weakened PFC function and, in this brain region, DAT density is low. 
Therefore, it is unlikely that DAT blockade is the only responsible for PFC changes 
observed after MPH use (Madras et al., 2005). Therefore, new attention was brought to 
the NA neurotransmitter and its transporter. Indeed, several studies showed that DA 
affinity for the NAT is higher when compared with its affinity for the DAT. Also, NAT 
density was higher than DAT density in the PFC, which explains both NA and DA increase 
in that brain region following MPH (Madras et al., 2005).  
Non-responsive patients to MPH therapy reaches in nearly 30% of ADHD patients, 
which might be explained by the broad mechanisms of ADHD. Non-responsiveness could 
reflect interindividual differences, namely very low DA activity, differences in the sensitivity 
or levels of DAT, differences in sensitivity of postsynaptic DA receptors and/or differences 
in the noradrenergic activity (Volkow et al., 2002, Volkow et al., 2005). 
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Table 1 – Main features of different MPH formulations available in the United States. Some of these formulations are also available in other countries. 
 
Formulation name 
Time to peak concentration 
(h) 
Duration of action 
(h) 
Available doses Reference 
Immediate Release 
Ritalin ® 1 – 3 3 – 4 5, 10, 20 mg (FDA, 2013b) 
Methylin ® 1 – 2 3 – 4 2.5, 5, 10 mg (FDA, 2009c) 
Focalin ® (dexmethylphenidate) 1 – 1.5 3 – 6 2.5, 5, 10 mg (FDA, 2013a) 
Intermediate–Acting 
Ritalin SR ®  4 – 5 8 20 mg (FDA, 2013b) 
Metadate ER ® 4 – 5 8 10, 20 mg (Sugrue et al., 2014) 
Methylin ER ® 3 – 4 8 10, 20 mg (Sugrue et al., 2014) 
Long-Acting (bi-modal plasma concentration-time profile, i.e., two distinct peaks approximately 4 h apart) 
Ritalin LA ® 
First peak: 1 – 3 
Second peak: 4 – 5 
8 – 10 10, 20, 30, 40 mg (FDA, 2013b) 
Metadate CD ® 
First peak: 1.5 
Second peak: 4.5 
8 
10, 20, 30, 40, 50, 60 
mg 
(FDA, 2009b) 
Concerta ® (osmotic release oral 
system)  
First peak: 1 – 2 
Second peak: 6 – 8 
12 18, 27, 36, 54, 72 mg (FDA, 2009a) 
Focalin XR ® 
(dexmethylphenidate) 
First peak: 1 – 4 
Second peak: 4.5 – 7 
12 
5, 10, 15, 20, 25, 30, 
35, 40 mg 
(FDA, 2011) 
Transdermal System 
Daytrana ® 9 
Depends on usage 
time 
10, 15, 20, 30 mg 
patches 
 (FDA, 2015) 
  
 
 
 
Part I - Introduction 
15 
 
1.2.1. Pharmacokinetics 
 
With a low absolute bioavailability, a high volume of distribution, a high lipid 
solubility, a low protein binding, and a pka around 8.8, MPH can easily cross cellular 
membranes and enter the brain (Moffat et al., 2011). The pharmacokinetic parameters are 
dependent of the stereoselective profile, the administration route, and the formulation of 
the drug. Additionally, there is considerable interindividual variability, rendering difficult the 
evaluation of several pharmacokinetic parameters (Faraj et al., 1974, Heal and Pierce, 
2006). 
 
1.2.1.1. Absorption 
 
Regardless of the route of administration [intraperitoneal (i.p.), intravenous (i.v.) or 
oral], MPH is rapidly absorbed. In case of oral administration, the absorption occurs in the 
gastrointestinal tract and the values of peak plasma concentration (Cmax) and half-life (t1/2) 
are dependent of the type of the formulation. For example, after the intake of IR-MPH by 
humans, Cmax occurs between 1-3 hours (h) and t1/2 between 2.6-3 h; on the other hand, 
ER formulations have values of Cmax and t1/2 slightly higher (3-4 h and 4.1 h, respectively) 
since these formulations are designed to assure therapeutic plasma drug levels for longer 
periods (Swanson and Volkow, 2002, Wolraich and Doffing, 2004, Barceloux, 2012). 
MPH is also characterized by a low absolute bioavailability due to an extensive 
presystemic metabolism as verified by Faraj and coworkers. They investigated the 
disposition of MPH in man, dog, and rodents after oral or i.v. administrations (Faraj et al., 
1974). The extensive presystemic metabolism was proven by higher plasma metabolites 
levels than MPH during the absorption phase, the pattern of urinary excretion of the 
radioactive isotope 14C and, ultimately, by the composition of urine (Faraj et al., 1974). 
The bioavailability of MPH following an oral dose (10-15 mg) ranges from 11-53% in 
humans (Chan et al., 1983), being the bioavailability of d-threo significantly higher than of 
l-threo (23% and 5%, respectively) after oral administrations of three different formulations 
(IR, ER swallowed whole with water or ER chewed before swallowing) each with 40 mg of 
MPH (Srinivas et al., 1993). In rats, the bioavailability also had a wide variation (8-44%) 
and it was found to be 19% after oral administration when compared with an identical i.v. 
dose (10 mg/kg) (Wargin et al., 1983). 
Due to the saturable presystemic metabolism, a nonlinear relationship between 
area under the plasma concentration-time curve (AUC) and oral dose was found either in 
studies in rats or humans (Aoyama et al., 1990, Aoyama et al., 1993). Significant 
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differences in other pharmacokinetic parameters like clearance, volume of distribution in 
steady state, AUC, and mean residence time were also reported regarding the two 
enantiomers (Srinivas et al., 1993). After i.v. administration of 10 mg of MPH to 11 healthy 
subjetcts, l-threo showed a clearance 2-fold higher than d-threo (67.99 L/h vs. 36.61 L/h), 
a shorter mean residence time (2.44 h vs. 6.53 h) and a volume of distribution in steady 
state 1.6-fold lower when compared to d-threo MPH (Srinivas et al., 1993). 
 
1.2.1.2. Distribution  
 
The tissue distribution and accumulation of MPH is rapid and occur by passive 
diffusion. Patrick and coworkers reported that, one minute after an i.v. administration of 
MPH (1 mg/kg), it was attained the peak brain concentration in male Sprague Dawley rats 
(Patrick et al., 1984). The accumulation was found to occur in the following magnitude: 
kidney > lung > brain > heart > liver 30 min after i.p. administration of MPH (20 mg/kg) in 
rats due to the low protein binding and high lipid solubility of MPH (Patrick et al., 1984, 
Wolraich and Doffing, 2004).  
This pharmacokinetic parameter is affected by the stereoselective metabolism 
mainly after oral administration, since plasma levels of d-threo-MPH were significantly 
higher than l-threo-MPH 30 minutes (Yang et al.) post-administration in humans. When 
using i.v. administration, the difference between enantiomers was only observed 1.5 h 
after the administration (Srinivas et al., 1993). 
Studies based on labeled d- and l-threo-MPH with 11C and analysis by PET 
allowed to better understand the distribution of MPH in the brain. At both 30 and 100 min 
after oral administrations in rats, Ding and coworkers reported a higher total fraction of 
radioactivity in the brain after administration of l-isomer labeled with 11C than after d-
isomer. Also, a higher uptake of d-threo was observed in the striatum, but not in the 
cerebellum following i.v. administration of d-isomer when compared with l-isomer (Ding et 
al., 2004). In addition, Faraj et al. detected an overall preferential uptake and 
accumulation of MPH to the brain when compared with plasma (Faraj et al., 1974). 
In humans, Volkow and coworkers showed a higher concentration of dl-threo-MPH 
in the striatum than in cortex or cerebellum, and estimated that approximately 8% of the 
dose (0.5 mg/kg via i.v.) entered into the human brain, reaching the peak uptake between 
4 to 10 min and the half peak clearance after 90 min (Volkow et al., 1995, Swanson and 
Volkow, 2002).  
These results evidence the striatum is the brain region where this isomer reaches 
higher levels (Swanson and Volkow, 2002). 
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1.2.1.3. Metabolism 
 
MPH suffers metabolic reactions like de-esterification, microsomal oxidation, and 
conjugation to give rise to, respectively, ritalinic acid (RA), p-hydroxy-MPH or oxo-MPH 
(also named lactam) and conjugated metabolites. In addition, both p-hydroxy-MPH and 
oxo-MPH can be transformed in p-hidroxy-RA and oxo-RA (Faraj et al., 1974, Kimko et 
al., 1999). The major metabolites are pharmacologically inactive but p-hydroxy-MPH is 
relatively lipid soluble, so, it is capable to cross the blood-brain barrier and may have 
some pharmacological activity (Hungund et al., 1979). The main metabolic pathways for 
MPH are depicted in Figure 2. 
In the rat, aromatic hydroxylation seems to be the predominant metabolic pathway 
since approximately one half of the metabolites found in the urine were p-hydroxy-MPH, 
p-hidroxy-RA and a glucuronide conjugate of p-hidroxy-RA. However, the products of de-
esterification and microsomal oxidation were also detected (Faraj et al., 1974). In humans, 
de-esterification is the major pathway responsible for MPH metabolism, but other 
pathways, like aromatic hydroxylation, microsomal oxidation, and conjugation give minor 
contributions (Faraj et al., 1974, Redalieu et al., 1982, Kimko et al., 1999). 
De-esterification is carried out by human liver carboxylesterase CES1A1, one of 
the most abundant carboxylesterase present in the liver and also in the gastrointestinal 
system. It shows a high catalytic efficiency for MPH, however, with different affinities for 
each enantiomer. CES1A1 carboxylesterase has a higher catalytic affinity for l-threo than 
for d-threo, which is consistent with the idea of a stereoselective metabolism of MPH (Sun 
et al., 2004, Heal and Pierce, 2006). 
The MPH metabolism is very fast since RA and MPH have peak levels at 
approximately the same time. With poor lipid solubility, RA is easily excreted. Secondary 
metabolites like p-hidroxy-RA and oxo-RA can also be excreted unchanged or conjugated 
with glucuronic acid (Faraj et al., 1974, Egger et al., 1981, Wargin et al., 1983). 
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Figure 2 – Main metabolic pathways of MPH and its metabolites. 
 
1.2.1.4. Excretion  
 
Urine is the major route of excretion for MPH and its metabolites but two other 
routes (bile and feces) also contribute to MPH excretion in rats (Faraj et al., 1974, Heal 
and Pierce, 2006). In rats, and based on 14C excretion, 48 h after i.p. or oral administration 
of dl-threo-MPH hydrochloride (HCl), 50 to 60% of marked 14C was excreted in the urine 
and 30 to 40% in feces. After a single dose via i.p., 25 to 30% of the dose was excreted in 
bile within 12 h. In humans, after oral administration, 90% of the 14C was excreted in the 
urine 48 h post-administration (Faraj et al., 1974). 
About 80% of the dose found in urine of humans is RA, the main MPH metabolite 
(Faraj et al., 1974). Significantly higher concentrations of the l-RA isomer than of the d-RA 
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were found in the first 2 h following oral administration of dl-threo-MPH HCl (40 mg) to 
humans, although that difference was not observed after i.v. administration of 10 mg of 
the same racemic mixture (Srinivas et al., 1992). 
Unchanged drug was also excreted in the urine but there are differences 
depending on the administration route. Between 0 and 2 h after oral administration of 
MPH in humans, the unchanged d-isomer was found in urine at 10 fold higher levels than 
the isomer l-; however, after i.v. administration, no evidence for enantioselective excretion 
was reported (Srinivas et al., 1992).  
 
1.3. Acute adverse effects of MPH  
 
Over recent years, the dramatic rise of patients diagnosed with ADHD and the 
increasing number of MPH prescriptions have raised concerns about the potential illicit 
use of this drug. In fact, MPH is classified as a Schedule II substance by the Drug 
Enforcement Agency, due to a high abuse potential that can lead to severe dependence 
(DEA, 2016). Moreover, accordingly to the Australian NSW Poisons Information Center, 
the number of intoxication reports with ADHD medication has increased dramatically 
during the recent years, being 62% of the reports associated to MPH use in the period 
between 2004 and 2014 (Cairns et al., 2016). Among the reasons to the misuse of this 
drug, the most frequent is the recreational purpose or to enhance academic performance. 
Since MPH has psychostimulant properties, it triggers symptoms like euphoria, greater 
sociability, behavioral disinhibition, and increased attention and concentration (Morton and 
Stockton, 2000, Cairns et al., 2016). Intentional overdoses in suicide attempts were also 
reported, and might be related to the high availability of MPH. Several case reports 
describe suicide attempts with the ingestion of a wide range of MPH doses by adolescents 
(210 – 1350 mg) (Fettahoglu et al., 2009, Klampfl et al., 2010, Ozdemir et al., 2010, Murat 
and Arman, 2013). Overdoses in preschoolers are also frequent following accidental 
ingestion caused by repeated or incorrect self-administered doses or given by a caregiver, 
and even caused by ingestion of the medication of a sibling (Foley et al., 2000). Although 
93% of these intoxications results of oral ingestion of MPH, other routes like nasal 
insufflation of crushed tablets and i.v. administration are used to obtain the desired effects 
(Scharman et al., 2007, Cairns et al., 2016).  
The manifestations of MPH acute toxicity results in symptoms similar to those 
observed after acute AMPH since these stimulants act at the same monoamine 
transporters (Morton and Stockton, 2000, Teixeira-Gomes et al., 2015). Neurological 
effects include irritability, euphoria, delusions, hallucinations, psychosis, aggressive 
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behaviors, and seizures. Additionally, cardiovascular effects like tachycardia, 
hypertension, and chest pain are also manifested (Morton and Stockton, 2000, Scharman 
et al., 2007). Although MPH intoxication symptoms are principally related to the CNS and 
cardiovascular system, other symptoms like fever, abdominal pain, and vomiting are also 
reported (Scharman et al., 2007). Hyperthermia, one of the most dangerous effect that 
can lead to rhabdomyolysis, acute renal failure, disseminated intravascular coagulation, 
multiple organ failure and, consequently, death have also been reported after severe 
intoxications of MPH (Scharman et al., 2007, Peyre and Delorme, 2012, Teixeira-Gomes 
et al., 2015).  
 
1.4. Long-term adverse effects of MPH 
 
The worldwide rise of MPH prescriptions has also created substantial concerns 
regarding the risks to the exposure to this stimulant since a prolonged exposure 
throughout the childhood or a lifetime administration is required in ADHD treatment. In 
2009, the Agency’s Committee for Medicinal Products for Human Use concluded that a 
lack of information on the long-term effects of MPH existed and that further research 
would be important to focus on the neurological and cardiovascular effects of patients that 
took or were taking MPH for the treatment of ADHD (EMEA, 2009). Actually, the CNS and 
the heart share several characteristics, namely low regenerative ability of some cells, 
excitability of some cell groups, and are both largely susceptible to differences in biogenic 
amines (Costa et al., 2013). These characteristics make both the CNS and the heart 
susceptible to some xenobiotics, like psychostimulants. Below are detailed studies 
regarding the adverse long-term effects of MPH in rats and humans. 
 
1.4.1. CNS effects of MPH 
 
Adolescence involves critical stages of neurodevelopment that can be highly 
influenced by psychostimulants, so, the administration of MPH can trigger long-lasting 
adaptive responses as a result of modifications in the internal organization and structural 
maturation of the brain. Moreover, these modifications can influence the behavior and the 
brain’s capabilities during adulthood (Moll et al., 2001, Bethancourt et al., 2009). Since 
studies involving children or adolescents are scarce for ethical reasons, most of the data 
existing on the CNS effects of MPH lies in studies with laboratory animals, namely rats 
between postnatal days (PND) 28 and 60, period that corresponds to adolescence in this 
animal model (Spear, 2000). 
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1.4.1.1. CNS effects of MPH on laboratory animals 
 
It is well established that repeated exposure to stimulants, like cocaine (which, like 
MPH, is a DAT inhibitor), is associated to significant neuroadaptations in the dopaminergic 
system. In fact, several authors evaluated neurophysiological changes after MPH chronic 
exposure and reported declines in brain DAT density (Moll et al., 2001, Marco et al., 
2011). Moll and coworkers used ligand-binding-assays to study DAT density in the 
striatum of Wistar rats 6 or 31 days after administration of MPH (2 mg/kg/day), via the 
drinking water, during 2 weeks to very young (PND 25) or late adolescent (PND 50) rats. It 
was observed that striatal DAT density declined by 25% 6 days after the discontinuation 
(PND 45), and about 50% after 31 days (PND 70) in the very young group of rats (MPH 
administrated at PND 25). These declines were not observed in the older rats. NAT and 5-
HTT were also studied but no differences were found between control and MPH treated-
rats (Moll et al., 2001).  
Differences in the striatal volume and myelination of adolescent and adult rats 
were also reported in the developing dopaminergic system after MPH administration. MPH 
(5 mg/kg, HCl salt) was orally administrated once daily for 21 days to Wistar rats with PND 
25 or PND 65 ± 4 days, and the brains were evaluated 1 week post-administrations (van 
der Marel et al., 2014). The results revealed a reduction of 1.6% in striatal volume, a 
decrease of 9.7% in myelin content in PND 25 animals, a 2.8% increase of striatal 
volume, and a 3.1% increase of myelin content in adult animals when compared to the 
respective controls (van der Marel et al., 2014).  
MPH also affects the structure and function of the brain, especially in 
hippocampus, which is involved in learning and memory processes (Banihabib et al., 
2014). In adult rats treated with MPH (3 or 10 mg/kg, orally), once daily, for 6 days, 
hippocampal necrosis was detected after the higher dose (Banihabib et al., 2014). 
Regarding adolescent rats, a significant loss of neurons and astrocytes in the 
hippocampus was reported by Schmitz and coworkers (Schmitz et al., 2016). MPH (2.0 
mg/kg) was administrated via i.p., once daily, between PND 15 and PND 45 and, 24h after 
the last administration, a significant decrease in the number of neurons and astrocytes 
was detected by flow cytometry when compared to the control group. Further studies were 
made in order to understand the underlying mechanisms of that cell death; however they 
only concluded that it did not involve necrosis (Schmitz et al., 2016). 
The increase of extracellular DA caused by MPH may also induce oxidative stress, 
since DA and NA can form reactive quinones or react with molecular oxygen and Fe2+ to 
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form reactive species, namely hydroxyl radical, superoxide anion radical (O2
•-) or H2O2 
(Gomes et al., 2009, Schmitz et al., 2012). After i.p. administration of 1.0, 2.0 or 10 mg/kg 
of MPH (HCl salt) once daily to young (PND 25) or adult (PND 60) Wistar rats during 28 
days it was observed, 2 h after the last injection, a dose-dependent increase on lipid 
peroxidation and protein carbonyl formation in the cerebellum, PFC, hippocampus, and 
striatum of young rats but not in adult rats (Martins et al., 2006). The authors performed 
another experiment using the same doses but evaluated the effects acutely: 1.0, 2.0 or 10 
mg/kg of MPH (HCl salt), i.p., was given only once to young (PND 25) or adult (PND 60) 
rats and the sacrifice was performed 2 h later. Among the adult groups, no differences 
were found, but in the young rats, lipid peroxidation decreased in the PFC, cerebellum, 
hippocampus, and striatum when compared to the respective control group (Martins et al., 
2006). Oxidative stress in the hippocampus after chronic treatment with high doses of 
MPH was reported by Motaghinejad and coworkers (Motaghinejad et al., 2016). Male 
Wistar rats with 8 weeks old received 2.0, 5.0, 10, and 20 mg/kg of MPH, via i.p., for 21 
days and 24 h after the treatment, lipid peroxidation and oxidized glutathione (GSSG) 
content increased in a dose-dependent manner, while reduced glutathione (GSH) content 
decreased (Motaghinejad et al., 2016). On the other hand, Schimitz and coworkers 
reported increased lipid peroxidation and protein damage in the PFC, but not in the 
cerebellum, striatum or hippocampus after Wistar juvenile rats received 2.0 mg/kg of MPH 
via i.p. once a day from  PND 15 to PND 45 (Schmitz et al., 2012). These results argue for 
a higher susceptibility of the younger rat brain to redox changes induced by MPH, and that 
these changes are dose and time of exposure dependent.  
The production of O2
•- in submitochondrial fractions was also evaluated to allow a 
better understanding of the toxicity mechanisms elicited by MPH treatment. Different 
doses of MPH (1.0, 2.0 or 10 mg/kg) were administered, via i.p., only once or chronically 
(during 28 days) to Wistar rats with PND 25 or PND 60 and the production of O2
•- in 
submitochondrial fractions of several brain areas was evaluated 2 h after the last 
administration (Gomes et al., 2009). The results revealed: (1) an increased production of 
mitochondrial O2
•- in the cerebellum (in all doses) and in the hippocampus (10 mg/kg) after 
acute administration in young rats; (2) a decreased production in the cerebellum (1.0 and 
2.0 mg/kg) after chronic administration in adult rats and, (3) no effects after chronic 
treatment in young rats or after acute treatment in adult rats. These results allowed the 
authors to conclude that MPH can influence the production of O2
•- in the brain but that 
effect is age and treatment dependent (Gomes et al., 2009). 
With the increase of reactive species, the enzymatic antioxidant defense system 
may be upregulated allowing the changes in antioxidant enzymes to prevent oxidative 
stress (Schmitz et al., 2012). Since oxidative stress was already reported after MPH 
Part I - Introduction 
23 
 
administration, authors evaluated the effects of MPH in the activity of two antioxidant 
enzymes, superoxide dismutase and catalase, after acute and chronic exposure (Gomes 
et al., 2008, Schmitz et al., 2012). MPH (1.0, 2.0 or 10 mg/kg) was administrated to young 
(PND 25) or adult (PND 60) Wistar rats, via i.p., only once (acute treatment) or once daily 
for 28 days (chronic treatment) and the animals were sacrificed 2 h after the last injection. 
In young rats, in the acute treatment, authors observed a decreased activity of superoxide 
dismutase in the PFC (1.0 mg/kg) and an increased activity in the cortex (all doses 
tested). A decreased activity of catalase was also observed in the hippocampus at the 1.0 
mg/kg dose (Gomes et al., 2008). After chronic treatment in PND 25 rats, the activity of 
superoxide dismutase increased in the hippocampus and cortex (1.0 mg/kg), but the 
activity of this enzyme was inhibited in the striatum after the same dose (1.0 mg/kg). At 
the 2.0 mg/kg dose an increased superoxide dismutase activity in the cortex was 
observed. The activity of catalase was not altered in none of the brain areas evaluated 
after chronic exposure to MPH in young rats. Relatively to adult rats, MPH acute or 
chronic treatment did not cause any change in the activities of superoxide dismutase or 
catalase at any given dose (Gomes et al., 2008). In another study, MPH (2.0 mg/kg, i.p.) 
was administered to Wistar rats with PND 15 during 30 days and that treatment led to an 
increased activity of superoxide dismutase in the cerebellum and PFC, but not in the 
striatum or hippocampus, and an increased activity of catalase only in the cerebellum 
(Schmitz et al., 2012). Overall, these results suggest that the MPH dose, the 
administration period and the brain region are important determinants for the regulation of 
antioxidant enzymes (Gomes et al., 2008, Schmitz et al., 2012). 
Regarding the energetic metabolism, several pathways have been discovered to 
be influenced by MPH administration. For example, altered brain mitochondrial activity 
has been reported in adult rats after acute and chronic exposure to MPH (Fagundes et al., 
2010b). A single injection of MPH (1, 2 or 10 mg/kg, via i.p.) or an injection once a day for 
28 days was given to adult Wistar rats (PND 60) and the results revealed that 
mitochondrial respiratory chain complexes I, II, III, and IV were inhibited in the 
hippocampus, PFC, striatum, and cerebral cortex either after the single dose or after the 
chronic exposure (Fagundes et al., 2010b). The exact same treatment schedule was 
performed in young Wistar rats (PND 25) and the results were completely different 
(Fagundes et al., 2010a). After the acute treatment, the results showed a reduction in the 
activity of complex I in the cerebellum and PFC and, after chronic treatment, the activities 
of complexes II and IV were increased in the younger animals (Fagundes et al., 2010a). 
In order to understand why the activity of the mitochondrial respiratory chain was 
altered after MPH and, consequently, how ATP production could be impaired, Reus and 
coworkers studied the activity of two enzymes involved in the Krebs cycle: citrate 
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synthase and isocitrate dehydrogenase (Reus et al., 2013). MPH HCl salt (1.0, 2.0 or 10 
mg/kg, via i.p.) was administrated, only once (acute treatment) or during 28 days (chronic 
treatment) to young (PND 25) or adult (PND 60) Wistar rats, which were sacrificed 2 h 
after the last injection. After analyzing the cerebellum, striatum, PFC, hippocampus, and 
cortex, the authors reported that chronic MPH exposure caused decrease activity on both 
enzymes, in all the brain areas of either young and adult animals while, after acute 
treatment, the activity of both enzymes was not altered in young rats while, in adult rats, 
only in the cerebellum a significant reduction on the enzymes was detected (Reus et al., 
2013). 
 Regarding the neurobehavioral component, an increasing bulk of studies has 
reported changes after childhood and adolescent exposures to MPH that persist in 
adulthood (Bolanos et al., 2003, Carlezon et al., 2003, Bethancourt et al., 2009, Scherer 
et al., 2010, Marco et al., 2011). Among those behavioral changes, the authors reported: 
(1) reduced sensitivity to reward stimuli (Bolanos et al., 2003, Carlezon et al., 2003), (2) 
enhanced responsivity to stressful situations (Bolanos et al., 2003), (3) depressive-like 
responses and reduced adaptation to a familiar environment (Carlezon et al., 2003), (4) 
transient effects on hippocampal-sensitive memory (Bethancourt et al., 2009), and (5) 
cognitive impairments in spatial reference and working memory tests (Scherer et al., 
2010). The experimental designs of these studies and their main findings are summarized 
in Table 2. 
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Table 2 – Experimental designs of neurobehavioral studies and the main findings after chronic exposure of infant or adolescent rats to MPH. 
 
 
Animal 
characteristics 
Dosage regimen Neurobehavioral task evaluated Promoted changes Reference 
     
Sprague Dawley 
rats were exposed 
from PND 20 to 
PND 35 
2.0 mg/kg, i.p., 
twice a day, 4 h 
apart 
Social play behavior, sucrose preference, 
locomotor response to a novel environment, 
elevated plus maze and self-grooming 
behavior, social interaction in an aversive 
environment, sexual behavior, and forced 
swim test. Play behavior task was conducted 
5 days after the last injection. The remaining 
tasks were conducted 6 weeks after the last 
injection. 
 
Decreased sucrose preference, 
increased anxiety-like behavior, 
more time engaged in self-
grooming, and deficit in sexual 
behavior at adulthood. 
(Bolanos et 
al., 2003) 
Sprague Dawley 
rats were exposed 
from 
PND 20 to PND 35 
2.0 mg/kg, i.p., 
twice a day, 4 h 
apart 
Place conditioning to cocaine, forced swim 
test, and locomotor activity levels. Behavior 
tests were conducted at PND 60. 
Reduced sensitivity to cocaine 
reward, increased depressive-
like responses, and reduced 
habituation to a familiar 
environment. 
(Carlezon et 
al., 2003) 
Wistar rats were 
exposed from PND 
27 to PND 71 
2.0 mg/kg or 5 
mg/kg, orally, 
twice a day, 6 h 
apart 
Open-field testing, novel object recognition 
testing, and contextual fear conditioning and 
testing. Behavior tests were conducted at 
PND 89. 
Increased latency to reach the 
criterion for sample object 
exploration and increased 
contextual fear memory. 
(Bethancourt 
et al., 2009) 
Wistar rats were 
exposed from PND 
15 to PND 45 
2.0 mg/kg, i.p., 
once a day 
Morris water navigation task, reference 
memory task, working memory test, and 
open-field task. Behavior tests were 
conducted at PND 46. 
Cognitive impairments of spatial 
reference and working memory 
tasks. 
(Scherer et 
al., 2010) 
  
 
Part I - Introduction 
27 
 
In addition to different neurobehavioral responses according to the animal age and 
dose regimen, variations among different animal strains are also reported after acute or 
chronic treatment with MPH (Yang et al., 2003). Yang and coworkers analyzed locomotor 
responses and behavior sensitization or tolerance in three different rat strains: Sprague 
Dawley (wild type), spontaneously hypertensive rats (SHR), and Wistar-Kyoto (strain 
control for SHR). The SHR rat is one of the most used animal model to investigate ADHD 
since exhibits similar behaviors to those of ADHD subjects (Yang et al., 2003). MPH (0.6, 
2.5 or 10 mg/kg) was administrated, via i.p., only once (acute treatment) to each 8-week-
old strain and, 2 h after the injection, locomotor activity was evaluated. The authors 
observed that the lowest dose had no significant effect in the locomotor activity, but a 
single injection of 2.5 mg/kg induced a more intense response in SHR rats than on the 
Sprague Dawley or Wistar-Kyoto rats. Regarding the highest dose, a single dose of MPH 
induced a more intense response in Sprague Dawley rats followed by Wistar-Kyoto, with 
SHR rats being the least responsive (Yang et al., 2003). The locomotor activity was also 
evaluated after a chronic treatment: MPH (0.6, 2.5 or 10 mg/kg, i.p.) was administrated to 
each strain for 6 consecutive days. After a washout period of 3 days, rats were exposed to 
a re-challenge with the same doses (0.6, 2.5 or 10 mg/kg) at the eleventh experimental 
day. Once again, the authors did not observe any differences after the re-challenge with 
the 0.6 mg/kg. Regarding the other doses, repeated exposure to 2.5 mg/kg induced 
behavioral sensitization in both Sprague Dawley and Wistar-Kyoto rats and the repeated 
administration of 10 mg/kg induced tolerance in the same strains. The SHR only exhibited 
locomotor tolerance after the re-challenge with the highest dose (Yang et al., 2003). 
 
1.4.1.2. CNS effects of MPH on humans 
 
Although neurotoxicity studies conducted in laboratory animals are important, 
studies in humans, especially in adults after chronic exposure to MPH during early-age 
may give critical data. However, those studies are still scare and, when available, are 
sometimes contradictory. In order to understand the effects of MPH therapeutic oral doses 
in children, adolescent or adult brains with ADHD, the structural and functional 
neuroimaging of unmedicated subjects with ADHD, medicated subjects with ADHD and 
control groups have been used (Schweren et al., 2013).  
Regarding the effects on brain structure, the analysis of structural MRI allowed to 
conclude that chronic exposure to MPH during childhood or adolescence probably 
attenuates specific structural brain abnormalities, like reduction in white matter volume of 
frontal, striatal, cerebellar and corpus callosum regions, since those reductions were 
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reported in unmedicated ADHD but not in medicated ADHD or in control groups 
(Schweren et al., 2013, Spencer et al., 2013).  
Measuring brain activity while at rest or during tasks through fMRI can also reveal 
the effects of MPH in domains like working memory, attention, reward processing, error 
processing or emotional processing (Schweren et al., 2013). After acute exposure during 
childhood or adolescence, MPH seems to normalize brain activity in the striatum, PFC, 
and anterior cingulated cortex (Schweren et al., 2013, Spencer et al., 2013). Although 
several studies confirmed attenuation in brain activity after oral administrations of MPH, 
other studies revealed opposite results. Sheridan and coworkers measured, by fMRI, the 
neural activity of PFC and its connectivity to the basal ganglia during a working memory 
test and the results showed that PFC activity increased when the subjects (adolescent 
girls with ADHD) were off medication and decreased when they under the effects of MPH 
(Sheridan et al., 2010). Other authors reported a significant reduction of functional 
connectivity between the nucleus accumbens and the basal ganglia, the medial PFC, and 
the temporal cortex after a double-blind, placebo-controlled, two-way study in healthy 
individuals (23 to 35 years old) after a single oral dose of MPH (40 mg) (Ramaekers et al., 
2013). 
Relatively to long-term effects, adult subjects with ADHD that had received MPH 
during childhood were evaluated through fMRI and it was suggested that a normalization 
of brain activity can occur: differences in brain activity during emotional and reward 
processing are reported in adult unmedicated subjects with ADHD, but not in subjects with 
ADHD medicated or control groups (Schweren et al., 2013). 
PET imaging has been also used for a better understanding of the possible effects 
of MPH. So far, only one study reported a long-term effect in adults (age mean, 30.9 
years) with ADHD after a daily dose of long acting MPH formulation (1 mg/kg) during one 
year (Wang et al., 2013). PET imaging measured DAT availability and the authors 
observed an increased DAT availability of approximately 24% in the ventral striatum when 
compared to healthy controls. This finding may explain the decrease in treatment efficacy 
and symptoms exacerbation during the weekend or holidays when the patient is 
medication free (Wang et al., 2013). 
More serious CNS events were associated to MPH after chronic treatment. An 11-
year-old boy with ADHD presented visual hallucinations after three years of daily MPH (30 
mg) (Porfirio et al., 2011). Another 12-year-old boy was diagnosed with cerebral arteritis 
after being treated with 10 mg of MPH twice daily for seven years (Trugman, 1988). The 
same diagnosis was given to an 8-year-old boy after he was treated with a daily dose of 
20 mg of MPH for a year and a half (Schteinschnaider et al., 2000). In the three cases, the 
symptoms disappeared with the discontinuation of the MPH treatment. 
Part I - Introduction 
29 
 
Altogether, the data regarding MPH treatment shows that, although MPH is overall 
safe and improves brain function, brain toxicity is not absent in all the population, so, 
studies are urgent to assess the risks.  
 
1.4.2. Cardiovascular effects 
 
Cardiovascular events as a result of chronic exposure are also a matter of concern 
because it is known that MPH is associated with increased heart rate (HR) and blood 
pressure (BP). Moreover, the increase in monoamine neurotransmitters is known to 
interfere with several cardiovascular functions (Charatan, 2006, Take et al., 2008). For 
example, DA increases myocardial contraction, causes coronary vasoconstriction or 
vasodilatation and DA receptors have an important role in the cardiovascular circulation 
(Cavallotti et al., 2002). Moreover, oxidation of neurotransmitters and oxidative stress can 
be implied on cardiotoxic events like heart failure and ischemia-reperfusion injury, and 
therefore after continuous administration of stimulants that are potent releasers of 
neurotransmitters, cardiotoxicity can arise as a long term effect (Costa et al., 2011, 
Carvalho et al., 2012). 
 
1.4.2.1. Cardiovascular effects of MPH on laboratory animals 
 
Pronounced lesions on myocardial ultrastructure and degenerative ultrastructural 
abnormalities in cardiac mitochondria have been documented after chronic exposure to 
this stimulant (Henderson and Fischer, 1995, Take et al., 2008). Swiss-Webster mice 
received MPH (0.5, 2.5 or 5.0 mg/kg, three times a week, i.p. or 5.0 mg/kg, once a day, 
orally) for periods of 4 or 14 weeks. Moreover, Sprague Dawley rats received MPH (2.0, 
20 or 100 mg/kg, i.p.) during periods of 3, 6, or 9 weeks prior to sacrifice. Although little or 
no recognizable differences were found in the myocardium of mice injected with 0.5 
mg/kg, in the remaining groups (that included mice and rats) MPH induced myocardial 
membrane accumulations and lamellations, both highly focal and were evident at the 
earliest time-points as well as 12 weeks after the treatment, which suggests persistent 
effects in the myocardium (Henderson and Fischer, 1995). In another report, MPH (5.0, 10 
or 20 mg/kg) was administered orally to PND 25 Wistar rats for 5 days/week during three 
months and, at the end of the third month, the left ventricular heart tissue was removed 
and it was analyzed by immunohistochemistry (Take et al., 2008). A dose-dependent 
increase of D2 expression in the myocytes and connective tissue was observed, which 
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was related with mitochondria degeneration or an increased number of mitochondria that 
led to myofibril structure disruption and local effusion (Take et al., 2008). 
 
1.4.2.2. Cardiovascular effects of MPH on humans 
 
Increased levels of NA and consequent sympathetic nervous stimulation have 
been initially associated to the cardiovascular events seen after MPH exposure, but it has 
been recognized that increases of DA in the brain and of adrenaline in plasma are also 
involved in the cardiotoxicity of this stimulant (Volkow et al., 2003). Moreover, treatment 
with MPH has been associated with minor but statistically significant mean increases in 
BP and HR within hours, 12 weeks or even after 12 weeks of administration in children 
and adult with ADHD (Stiefel and Besag, 2010). After analyzing several placebo-
controlled studies, Rapport and Moffitt reported an increase HR ranging from 3 to 10 
beats per minute and an increase systolic BP and diastolic BP ranging, respectively, from 
3.3 to 8 mmHg and 1.5 to 14 mmHg as a result of short-term administrations of MPH in 
children (Rapport and Moffitt, 2002). Meta-analysis of published clinical trials reported in 
adults an increase in HR of 5.7 beats per minute and an increase of 2 mmHg in systolic or 
diastolic BP, when compared with randomized placebo subjects with a mean treatment 
exposure of 6 weeks (minimum of 4 weeks and maximum of 24 weeks) (Mick et al., 2013).  
Very serious cardiotoxic events have also been reported in different situations. 
Two adult men with 35 and 37-year-old suffered cardiac arrhythmias after receiving an i.v. 
dose of 0.3 mg/kg MPH (Lucas et al., 1986). Another 27-year-old man with adult attention 
deficit disorder was diagnosed with acute myocardial infarction, probably secondary to 
coronary vasospasm, 24 h after he ingested 25 mg of MPH (Thompson and Thompson, 
2010). An 18-year-old man suffered acute dilated cardiomyopathy one year after daily 
intake of MPH (54 mg) (Nymark et al., 2008). Cardiac arrest with pulseless electrical 
activity was also reported in an adolescent after 18 months with a daily dose of 36 mg of 
MPH (Daly et al., 2008). Chronic exposure to MPH was also linked to cardiac arrest 
following myocardial infarction in an 11-year-old boy that had two years with a daily dose 
of 54 mg (Munk et al., 2015). 
Sudden deaths were also linked to MPH administration in the data collected 
between January 1992 and February 2005 in the Unites States of America by the FDA 
(FDA, 2006). Among those cases, fourteen were children aged from 1 to 18 years and 
four were adult (older than 18). Their deaths were associated with MPH usage, although 
six pediatric cases revealed structural cardiovascular abnormalities in the autopsies that 
may had increased their cardiovascular risk (FDA, 2006).  
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2. Aims of the Study 
 
The increasing use and abuse of MPH has raised great concerns regarding the 
possible long-term effects on the neurobiology and development, mainly of adolescents 
since their brain is not fully mature. Additionally, deleterious cardiovascular events can be 
induced by catecholamine excess, whereby, heart structure and function can be altered in 
MPH treated patients. Therefore, a better understanding of the consequences of an early 
exposure to this drug used in ADHD treatment is essential. Specifically, it is necessary to 
understand the specific neuroadaptations and cardiovascular events underlying the 
chronic exposure to MPH in order to prevent and/or treat them.  
The main aim of this dissertation was to assess the adverse effects of this drug in 
an adolescent rat model (PND 40) after a one-week exposure to a dose scheme that 
mimics the therapeutic doses taken by adolescents during the treatment of ADHD, mainly 
focusing on MPH brain and cardiac effects. The effects were evaluated in four different 
brain areas (cerebellum, PFC, hippocampus, and striatum) and in three peripheral organs 
(liver, heart, and kidneys) 24 h after the last administration. To achieve the aims, several 
determinations like energetic content, redox status, quinoproteins formation, and protein 
carbonylation were performed. Additionally, histological analysis on the three peripheral 
organs was done and the levels of plasma enzymes of liver or heart damage was 
assessed. 
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3. Materials and Methods 
 
3.1. Materials 
 
MPH (HCl salt) was purchased from Tocris Bioscience (Bristol, UK). 
Ethylenediaminetetraacetic acid (EDTA), perchloric acid (HClO4), sodium hydroxide 
(NaOH), sodium carbonate (Na2CO3), disodium phosphate (Na2HPO4), cupper (II) 
sulphate (CuSO4), potassium bicarbonate (KHCO3), potassium dihydrogen phosphate 
(KH2PO4), magnesium sulphate (MgSO4), and Folin-Ciocalteu reagent were purchased 
from Merck (Darmstadt, Germany). Phosphate buffered saline solution (PBS) was 
purchased from Biochrom (Berlin, Germany), sodium chloride (NaCl), and sodium dodecyl 
sulphate (SDS) from VWR (Leuven, Belgium), potassium sodium tartrate from Fluka 
(Buchs SG, Switzerland), methanol, and xylene from Fisher Scientific (Loughborough, 
UK). Harris hematoxylin was purchased from Harris Surgipath (Richmond, IL, USA), eosin 
1% aqueous from Biostain (Traralgon, Australia), and Histofluid from Marienfeld (Lauda-
Königshofen, Germany). EMLA® Lidocaine 25 mg/g + Prilocaine 25 mg/g was obtained 
from AstraZeneca (London, UK). Isoflurane (Isoflo® 100% p/p) was obtained from Abbott 
Animal Health (North Chicago, IL, USA). ABX Pentra reagents were purchased from 
HORIBA (Kyoto, Japan). DCTM Protein Assay kit and the ClarityTM Western ECL Substrate 
were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Dinitropenhyl-KLH 
rabbit IgG antibody was purchased from Invitrogen/Life Technologies (Grand Island, NY, 
USA). Horseradish peroxidase (HRP) conjugated anti-rabbit antibody, slot blot apparatus 
and 0.45 μm Amersham Protran nitrocellulose blotting membrane were purchased from 
GE Healthcare Bio-Sciences (Pittsburgh, PA, USA). All the other chemicals used were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
3.2. Animals 
 
Fourteen adolescent male Wistar rats at PND 40 and weighing an average 120 g 
were born in the animal facilities of the Institute for Biomedical Sciences Abel Salazar, 
University of Porto (ICBAS-UP). Animals were kept in a controlled environment (23°C, 
55% humidity, 12h light/dark cycles) with food and water available ad libitum. All 
procedures were performed in order to minimize animal suffering and stress. Housing and 
experimental treatment were based in the guidelines defined by the European Council 
Directive (2010/63/EU) transposed into Portugal law (Decreto-Lei n. º 113/2013). 
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Additionally, the experiments were approved by the Ethical Committee of the Faculty of 
Pharmacy, University of Porto (process n. º 17/03/2014) and the Portuguese National 
Authority for Animal Health (General Directory of Veterinary Medicine) (process n. º 
0421/000/000/2015). 
 
3.3. Experimental protocol 
 
One-week prior to MPH administration, the dorsocervical region of each animal 
was trichotomised and anesthetized locally with a local anaesthetic (EMLA ® Lidocaine 25 
mg/g + Prilocaine 25 mg/g) that acted for about 60 min. Next, under a brief inhalatory 
anaesthesia with isoflurane, a subcutaneous insertion of a temperature transponder 
(BioMedic Data Systems Inc., Seaford, DE) was made to allow precise core body 
temperature measurements throughout the experimental period. In the following days, 
animals were maintained in groups to allow socialization and experienced a daily training 
to the sound of the temperature measurement device. Additionally, the animals were 
trained to receive oral administrations, by syringe, of a 5% sucrose solution. This was 
done in order to ensure an easy, complete and rapid drug intake during the treatment 
period. Cornflakes were given along the oral administration as a reward and to make sure 
that the solution was really swallowed. Twenty-four hours before the experiment and for 
the next seven days, the animals were individually housed with continuous access to food 
and water ad libitum. 
At PND 40, the fourteen male Wistar rats were randomly assigned to the two 
experimental groups: control (n = 7) and MPH-treated (n = 7). The MPH-treated group 
received two doses (one in the morning at 9 a.m., and other in the afternoon at 2 p.m., 5 h 
apart) of 5 mg/kg MPH previously prepared in sterile sucrose 5% solution. Controls 
received an equal volume of 5% sucrose in the same scheme. To more closely simulate 
the clinical use of MPH, we used low doses of oral MP administered to young rats divided 
in two daily intakes. The doses were selected on the basis of pharmacokinetic modeling to 
achieve peak plasma levels near the clinical range, and were previously used by other 
groups (Kuczenski and Segal, 2002, van der Marel et al., 2014). 
Before each morning administration, animals were weighted in order to adjust the 
dose to the individual weight and to assess possible changes in weight. Body temperature 
was also monitored and registered before each dose, 30 min after the administration and, 
after that, every 15 min for a total of 2.5 h. Food and water intake were also measured, 
daily, throughout the 7 experimental days. Twenty-four hours after the last administration, 
rats were sacrificed and brain areas (cerebellum, PFC, hippocampus, and striatum), 
Part III – Materials and Methods 
39 
 
peripheral organs (liver, heart, and kidneys) and blood were collected for posterior 
analysis.  
 
3.4. Blood and tissue collection 
 
The animals were anesthetized with isoflurane, a volatile anaesthetic and, before 
decapitation, blood was collected from the inferior vena cava to determinate the levels of 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine-kinase MB 
(CK-MB) and total creatine kinase (total-CK). After sacrifice, the brain was collected, 
weighted and dissected into four areas (cerebellum, PFC, hippocampus and striatum) 
according to a rat brain atlas (Swanson, 2004). The liver, heart, and kidneys were also 
collected and weighted.  
The brain areas dissected from the left hemisphere were placed in HClO4 5% (w/v) 
and homogenized in a sonicator (20 seconds, continuously) while the tubes were on ice. 
The resulting homogenates were then centrifuged (13,000 rpm, 10 min, 4ºC) and the 
supernatants were aliquoted and stored at -80ºC for posterior determination of total 
glutathione (GSHt), GSSG, and adenosine 5'-triphosphate (ATP). The pellet was kept at -
20ºC for protein determination. The brain areas dissected from the right hemisphere were 
collected in RIPA buffer supplemented on the day of sacrifice with protease and 
phosphatase inhibitors [150 mM NaCl, 50 mM Tris, 0.1% SDS (v/v), 0.5% sodium 
deoxycholate (m/v), 1% Triton X-100 (v/v), 0.25 mM phenylmethanesulfonyl fluoride 
(PMSF), 1 mM sodium metavanadate (NaVO3), 10 mM sodium fluoride (NaF), protease 
inhibitor cocktail from Sigma, pH = 8.0]. The samples were then homogenized in a 
sonicator (20 seconds, continuously) while kept on ice, and the homogenates were 
centrifuged (13,000 rpm, 10 min, 4ºC). The supernatants were aliquoted and stored at -
80ºC for posterior analysis of quinoprotein levels and protein carbonylation.  
Regarding the peripheral organs, after being weighed, a 2 mm section of each 
organ from four controls and four MPH-treated rats was collected and fixed in a 4% 
paraformaldehyde solution in PBS for further histologic analysis. A section of liver, heart, 
or kidneys from all animals was collected in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% 
SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 0.25 mM PMSF, 1 mM NaVO3, 10 mM 
NaF, protease inhibitor cocktail from Sigma, pH = 8.0). These samples were homogenized 
in a sonicator (30 seconds, continuously) while the tubes were on ice and the 
homogenates were centrifuged (5,000 rpm, 10 min, 4ºC). The supernatants were then 
aliquoted and stored at -80ºC for quinoprotein levels and protein carbonylation 
determinations. The remaining organs were homogenized in an Ultra-Turrax while in 0.1M 
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KH2PO4 (pH = 7.4). A homogenate aliquot was stored at -20ºC for protein quantification. 
Another aliquot was added to HClO4 10% (w/v) in a reason 1:1 and the solution was 
centrifuged (13,000 rpm, 10 min, 4ºC). The supernatants were then separated and stored 
at -20ºC for GSHt and GSSG determination and at -80ºC for ATP determination. All the 
procedures were performed on ice. 
 
3.5. Measurement of plasma biomarkers 
 
The blood from the inferior vena cava was collected into EDTA-containing tubes 
and, after centrifugation (920g, 10 min), the obtained plasma was stored at -20ºC until 
determination of ALT, AST, CK-MB and total-CK. The plasma biomarkers were 
determined through enzymatic assays in the apparatus ABX Pentra 400 with ABX Pentra 
reagents, according to the manufacturer’s instructions. The determinations were 
performed by Dra Laura Pereira, at the clinical analysis laboratory of the Faculty of 
Pharmacy of the University of Porto. 
 
3.6. Measurement of ATP levels 
 
ATP levels of the four brain areas and of the three peripheral organs were 
determined by a bioluminescent assay based in the luciferin-luciferase reaction (Capela et 
al., 2007, Costa et al., 2007). Aliquots of D-luciferin 90.9 mg/l stock reagent and luciferase 
from Photinus pyralis (firefly) (3 x 106 light units/ml) were first prepared in a luciferin-
luciferase buffer [50 mM glycine, 10 mM MgSO4, 1 mM Tris, 0.55 mM EDTA, 0.1% bovine 
serum albumin (BSA) (m/v), pH = 7.6] and stored at -80ºC, protected from light until use. 
These stock solutions were mixed in the day of the ATP determination. An ATP calibration 
curve was prepared in HClO4 5% (w/v) with concentrations ranging from 0.5 to 10 µM. At 
the day of the assay, 150 µl of samples, standards or blanks were neutralized with an 
equal volume of 0.76 M KHCO3, and, after a quick centrifugation (13,000 rpm, 1 min, 4ºC), 
100 µl of the supernatants were placed in a 96-well white microplate. Then, 100 µl of 
luciferin-luciferase reagent solution previously prepared was added to each well and 
bioluminescence was immediately read in a microplate reader Biotech Synergy HT (VT, 
USA). In order to avoid loss of bioluminescence signal and residual bioluminescence, a 
maximum of 6 measurements were made in each reading. The results were expressed as 
nmol of ATP per mg of protein (nmol ATP/mg protein). 
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3.7. Measurement of GSHt, GSH, and GSSG 
 
The GSHt and GSSG levels of the different brain areas and the peripheral organs 
were evaluated by the 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB)-GSSG reductase 
recycling assay (Capela et al., 2007, Costa et al., 2007). For the GSHt assay, 200 µl of 
samples, standards or blanks were neutralized with 200 µl of 0.76 M KHCO3, vortexed, 
and centrifuged (13,000 rpm, 5 min, 4ºC). In a 96-well microplate, 100 µl of neutralized 
blanks, standards or samples were added in triplicate and mixed with 65 µl of the reagent 
solution containing 0.68 mM nicotinamide adenine dinucleotide phosphate (NADPH) and 
3.96 mM DTNB freshly prepared in a phosphate buffer (71.5 mM Na2HPO4, 71.5 mM 
NaH2PO4, 0.63 mM EDTA, pH = 7.5). The 96-well microplate was then incubated in a 
Biotek PowerWaveX plate reader (VT, USA) for 15 min at 30ºC. After that, 40 µl of fresh 
glutathione reductase solution (10 U/ml in phosphate buffer) was added to each well. The 
stoichiometric formation of 5-thio-2-nitrobenzoic acid was monitored for 3 min at 10 
seconds intervals, at 415 nm, and compared with the calibration curve. Standards were 
prepared in HClO4 5% (w/v) with concentrations ranging between 0.5 and 15 µM.  
For the GSSG assay, before neutralization, 10 µl of 2-vinylpyridine was added to 
the acidic homogenates, standards or blanks and mixed for 1 h, on ice and under agitation 
in order to block GSH. After this period, the determination of GSSG was performed as 
described above for GSHt. GSSG standards were also prepared in HClO4 5% (w/v) and 
concentrations ranged from 0.25 to 8 µM. Moreover, the levels of GSH were calculated by 
the formula: GSH = GSHt – 2 x GSSG. The results of GSHt, GSH, and GSSG were 
normalized to the total protein content and were expressed as nmol of GSH or GSSG per 
mg of protein (nmol GSH/mg protein, or, nmol GSSG/mg protein). 
 
3.8. Quinoprotein assay 
 
The levels of protein-bound quinones (quinoproteins) in the brain and peripheral 
organs were determined by the nitrotetrazolium blue chloride (NBT)/glycinate colorimetric 
assay, as previously described (Capela et al., 2007). Twenty-five μg of protein lysates in 
RIPA buffer were added to 2 M potassium glycinate solution (pH = 10) to obtain a final 
volume of 250 μl. Then, 500 μl of NBT reagent (0.24 mM NBT in 2 M potassium glycinate, 
pH = 10) was added to start the reaction. The reaction occurred for 3 h, under agitation, at 
room temperature and protected from light. One hundred μl of the samples was added in 
triplicate and the absorbance was read at 530 nm in a 96-well microplate reader (Biotek 
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PowerWaveX plate reader, VT, USA) to assess the formation of the blue-purple colored 
complex between quinoproteins and the reagents. The results were expressed in optical 
density (OD) per mg of protein (OD/mg protein). 
 
3.9. Protein carbonylation assay 
 
As an index of protein oxidation, protein carbonyls in the brain and peripheral 
organs were determined by the reaction between 2,4-dinitrophenyllhydrazine (DNPH) and 
protein carbonyls and the subsequent detection of the dinitrophenyl hydrazine adduct. All 
samples were diluted in complete RIPA to a final concentration of 0.1 mg/ml. Next, 200 µl 
of SDS 12% (w/v) was added to 200 µl of samples containing 20 µg of protein. Samples 
were then incubated with 400 µl of 20 mM DNPH in 10% trifluroacetic acid (v/v) for 30 
min, at room temperature and protected from the light. After incubation, samples were 
neutralized with 300 µl of neutralization solution [18% β-mercaptoethanol (v/v) in 2 M Tris] 
and centrifuged at 13,000 rpm for 2 min. The supernatants were diluted in PBS to obtain a 
final concentration of 1 ng protein/µl. Using a slot blot apparatus (Amersham Life Science, 
Richmond, USA), 100 µl of the derivatized proteins were then loaded, under vacuum, into 
the nitrocellulose membranes (Hybond ECL, Amersham Pharmacia Biotech) previously 
hydrated in 10% methanol for a few seconds and 2-3 min in distilled water. Next, the 
membranes were washed in TBS-T [20 mM Tris base, 300 mM NaCl, 0.05% Tween 20 
(v/v), pH = 8.0], and blocked in the blocking buffer [5% milk (w/v) in TBS-T] for 1h, under 
agitation, at room temperature. The membranes were then incubated with primary 
antibody (rabbit polyclonal anti-DNP, 1:1000) overnight, at 4ºC. In the next day, 
membranes were washed five times (10 min each), under agitation, with TBS-T and the 
secondary antibody (anti-rabbit IgG-peroxidase, 1:2000) was added for 1h, under 
agitation, at room temperature. Both antibodies were diluted in the blocking buffer. 
Following three washes (10 min each) with TBS-T under agitation, the detection of 
immunoreactive bands was possible through the use of the ClarityTM Western ECL 
Substrate, used according to the manufacturer’s instructions. Digital images were 
acquired by a Molecular Imager ® ChemiDocTM XRS+ System (Bio-Rad Laboratories, 
CA, USA) and analyzed by the Image LabTM Software (Bio-Rad Laboratories, CA, USA). 
Results of OD were expressed as percentage of control values (% of control). 
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3.10. Histological treatment and analysis 
 
The 2 mm sections of liver, heart, and kidneys of four controls and four MPH-
treated rats were fixed overnight in a solution of 4% paraformaldehyde (m/v) in PBS at 
4ºC, dehydrated with grade ethanol solutions (70%, 80%, 95%, and 100%), cleared with 
xylene and, finally, embedded in paraffin in an oven at 56ºC. Paraffin sections with 5 μm 
thickness were then obtained in a manual rotator microtome Leica RM2125 (Wetzlar, 
Germany). The tissues were stained with hematoxylin and eosin as follows: 5 min xylene 
(2x), 5 min ethanol 100%, 5 min ethanol 95%, 5 min ethanol 80%, 5 min ethanol 75%, 5 
min water, 5 min hematoxylin, 8 min running water, 5 min eosin, 5 min ethanol 95%, 5 min 
ethanol 100%, 5 min xylene, and mounted with DPX. All preparations were analyzed with 
a Carl Zeiss Imager A1 light microscope and images were recorded with a coupled 
AxioCam MRc 5 digital camera (Oberkochen, Germany). 
 
3.11. Collagen detection and analysis 
 
The paraffin sections of liver, heart, and kidneys were also stained with Picrosirius 
Red as follows to detect collagen deposition: 5 min xylene (2x), 5 min ethanol 100%, 5 
min ethanol 95%, 5 min ethanol 80%, 5 min ethanol 75%, 5 min water, 90 min 0,1% sirius 
red dissolved in saturated aqueous picric acid, rinsed twice in 0.5% acetic acid, 5 min 
ethanol 95%, 5 min ethanol 100%, 5 min xylene, and mounted using DPX. All 
preparations were first evaluated in a Nikon Eclipse TS100 microscope with a coupled 
Nikon DS-Fi1 camera (Japan) and then analyzed with ImageJ (NIH, Bethesda, Maryland, 
USA). The results are expressed as percentage of collagen area (stains red) by muscle 
area (stains yellow) (% collagen/muscle area). 
 
3.12. Protein quantification 
 
In general, the protein content was determined by the Lowry method  (Lowry et al., 
1951). Protein standards were prepared with BSA in 0.5 M NaOH, and the standard curve 
ranged from 25 μg/ml to 250 μg/ml. To a 96-well microplate, 50 μl of samples, standards 
or blanks were added in triplicate and mixed with the freshly prepared reagent A (9.8 ml of 
2% Na2CO3, 100 μl of 2% sodium potassium tartrate and 100 μl of 1% CuSO4). After 10 
min in the dark, 100 μl of extemporaneously prepared reagent B (Folin-Ciocalteu reagent 
and water, 1:14) was added and the microplate was kept in the dark for more 20 min, after 
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which the absorbance was measured at 750 nm in a 96-well microplate reader (Biotek 
PowerWaveX plate reader, VT, USA).  
Regarding the samples containing complete RIPA buffer, namely for the 
quinoprotein and protein carbonylation assays, the protein content was determined by the 
DCTM Protein Assay kit from Bio-Rad, according to the manufacturer’s instructions.  
 
3.13. Statistical analysis 
 
Results are expressed as mean ± standard deviation (SD). Statistical analysis of 
the temperature, as well as animal weight, food and water intake was carried out by the 
two-way analysis of variance (ANOVA) with repeated measurements test, followed by a 
Bonferroni post-hoc test. When comparisons were done between the two studied groups 
at the end of the time-point, statistical comparisons were performed by the t-test when 
data followed a normal distribution or by the Mann-Whitney Rank Sum test when data did 
not pass the normality test. Differences were considered significant at p values lower than 
0.05. Outliers were identified using the ROUT’s test. All analyses were performed using 
GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). 
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4. Results 
 
4.1. MPH treatment had no effect on core temperature, 
body weight gain, and food/water intake in adolescent 
rats  
 
MPH (5 mg/kg in a 5% sucrose solution) or 5% sucrose (m/v) were orally 
administrated, twice a day, 5 hours apart, for seven days to adolescent rats and the body 
temperature, weight, and food/water intake were daily measured throughout the 
experimental period. In Figure 3, the results of the daily temperature in the first day 
(Figure 3A and 3B) and seven days later (Figure 3C and 3D) are presented after each 
dose. No significant differences were found between the control and MPH-treated group. 
Daily temperature between day 2 and 6 were also analyzed and no differences were 
found among groups after each dose (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Part IV- Results 
 
48 
 
T im e  (m in u te s )
T
e
m
p
e
r
a
tu
r
e
 (
º
C
)
0 3 0 4 5 6 0 7 5 9 0 1 0 5 1 2 0 1 3 5 1 5 0
3 6
3 7
3 8
3 9
4 0
C o n tro l
M P H
T im e  (m in u te s )
T
e
m
p
e
r
a
tu
r
e
 (
º
C
)
0 3 0 4 5 6 0 7 5 9 0 1 0 5 1 2 0 1 3 5 1 5 0
3 6
3 7
3 8
3 9
4 0
C o n tro l
M P H
T im e  (m in u te s )
T
e
m
p
e
r
a
tu
r
e
 (
º
C
)
0 3 0 4 5 6 0 7 5 9 0 1 0 5 1 2 0 1 3 5 1 5 0
3 6
3 7
3 8
3 9
4 0
C o n tro l
M P H
T im e  (m in u te s )
T
e
m
p
e
r
a
tu
r
e
 (
º
C
)
0 3 0 4 5 6 0 7 5 9 0 1 0 5 1 2 0 1 3 5 1 5 0
3 6
3 7
3 8
3 9
4 0
C o n tro l
M P H
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 –Temperature monitoring of rats in the first day of the experimental protocol after the first 
dose in the morning (A) and the second dose in the afternoon (B), and in the last day after the first 
dose in the morning (C) and the second one in the afternoon (D). Results, in degrees Celsius (ºC), 
are expressed as mean ± SD, from seven animals in each group. Statistical analysis was made 
using the two-way ANOVA followed by the Bonferroni post hoc test. 
  
Regarding the body weight gain per day and food or water intake (per day and per 
weight), no significant differences were found between the two studied groups. However, 
data showed a tendency for a decreased weight gain in the MPH-treated group (Figure 
4A). Even so both food and water intake were similar between the two groups (Figure 4B 
and 4C, respectively).  
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Figure 4 – Body weight gain per day (A), food (B), or water (C) intake per day and per weight of 
control and MPH-treated animals. Results in percentage of initial weight, in g/day or g/day/g, from 
seven animals in each group are expressed as mean ± SD. Statistical analysis was made using 
two-way ANOVA followed by the Bonferroni post hoc test. 
 
4.2. The weight ratio of peripheral organs was not altered 
by MPH treatment 
 
 The weight of each collected organ (liver, heart, kidneys, and brain areas) was 
registered. The weight ratio of each peripheral organ was calculated in relation to the 
brain weight. No significant differences were observed between control and MPH-treated 
rats (Table 3). 
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Table 3 – Organ weight ratio of control and MPH-treated rats. 
 Control MPH 
Liver weight/Brain weight 
ratio 
4.47 ± 0.40 4.48 ± 0.44 
Heart weight/Brain weight 
ratio 
0.40 ± 0.04 0.42 ± 0.04 
Kidneys weight/Brain 
weight ratio 
0.88 ± 0.08 0.93 ± 0.08 
 
Results, from seven animals in each group, are expressed as mean ± SD. The mean brain weight 
of the control group was 1.59 ± 0.06 g, and of MPH-treated group was 1.61 ± 0.04 g. Statistical 
analysis was made using the t-test. 
 
4.3. Plasma biomarkers of liver and heart damage were not 
changed by MPH treatment 
 
The levels of plasma biomarkers in control and MPH-treated rats were determined 
in order to detect liver (ALT and AST) or heart damage (AST, CK-MB, and total-CK). The 
results showed no significant differences for any biomarker measured 24 h after the 
exposure to MPH during seven consecutive days (Table 4).  
 
Table 4 – Biochemical plasma biomarkers of control and MPH-treated rats. 
 Plasma Levels 
Biomarker Control MPH 
AST (U/L) 166 ± 78 122 ± 37 
ALT (U/L) 39 ± 9 38 ± 5 
AST/ALT ratio 4.14 ± 1.42 3.17 ± 0.72 
CK-MB (U/L) 664 ± 375 809 ± 157 
Total-CK (U/L) 788 ± 549 964 ± 377 
 
Plasma levels of AST, ALT, CK-MB, and total-CK of control and MPH-treated group. Results, in 
units per liter (U/L), are expressed as mean ± SD. Data were obtained from seven animals in each 
group, except for the CK-MB and total-CK levels of the control group that were obtained from five 
animals. Statistical analysis was made using the t-test for AST and ALT levels, and the Mann-
Whitney Rank Sum test for CK-MB and total-CK levels. 
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4.4. ATP levels in the PFC show a tendency to decrease 
after MPH treatment 
 
The ATP levels were determined 24 h after the seven days treatment and showed 
no significant differences in the cerebellum, hippocampus, and striatum, as can be seen in 
Figure 5A, 5C, and 5D, respectively. However, data showed a strong tendency for a 
decrease (p = 0.051) in ATP levels in the PFC (Figure 5B) of adolescent rats after oral 
administration of MPH (5 mg/kg) for seven days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – ATP levels in the cerebellum (A), PFC (B), hippocampus (C), and striatum (D) of control 
and MPH-treated rats. Results, in nmol ATP/mg protein, from seven animals in each group are 
expressed as mean ± SD. Statistical analysis was made using the t-test. 
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4.5. MPH treatment reduced oxidative stress in the PFC 
and in the hippocampus  
  
The levels of GSHt, GSSG, GSH, and the GSH/GSSG ratio in the PFC are 
presented in Figure 6. As observed, a significant increase in the GSH/GSSG ratio (p = 
0.03) (Figure 6D) was found in rats treated with MPH. A strong tendency for a decrease (p 
= 0.050) in the GSSG levels was also detected. The remaining parameters in this area 
were not different among the two studied groups (Figures 6A, 6B, and 6C).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Levels of GSHt (A), GSSG (B), GSH (C), and GSH/GSSG ratio (D) in the PFC of control 
and MPH-treated rats. Results, in nmol/mg protein or in GSH/GSSG ratio, are expressed as mean 
± SD from seven animals in each group. Statistical analysis was made using the t-test for GSSG 
and GSH levels, and the Mann-Whitney Rank Sum test for GSHt and GSH/GSSG ratio levels 
(
*
p<0.05 vs. control). 
 
In Figure 7 are presented the levels of the four glutathione parameters evaluated in 
the hippocampus. MPH-treated rats showed a significant decrease of the levels of GSSG 
(p = 0.04) and a significant increase of the GSH/GSSG ratio (p = 0.006) (Figure 7B and 
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7D, respectively). No significant alterations were found in the levels of GSHt or GSH 
(Figure 7A and 7C, respectively) among both groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Levels of GSHt (A), GSSG (B), GSH (C), and GSH/GSSG ratio (D) in the hippocampus 
of control and MPH-treated rats. Results, in nmol/mg protein or in GSH/GSSG ratio, are expressed 
as mean ± SD from seven animals of each group. Statistical analysis was made using the t-test 
(
*
p<0.05 vs. control, 
**
p<0.01). 
 
The levels of GSHt, GSSG, GSH, and GSH/GSSG ratio in the cerebellum and 
striatum are represented in Table 5. No significant differences were observed in these two 
referred brain areas among control and MPH-treated groups.  
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Table 5 – Glutathione parameters in the cerebellum and striatum of control and MPH-treated rats. 
 Cerebellum Striatum 
Parameter Control MPH Control MPH 
GSHt (nmol/mg 
protein) 
14.2 ± 0.8 14.3 ± 1.7 20.3 ± 6.4 22.9 ± 1.2 
GSSG (nmol/mg 
protein) 
0.8 ± 0.1 0.8 ± 0.2 1.0 ± 0.5 1.2 ± 0.4 
GSH (nmol/mg 
protein) 
12.6 ± 0.8 12.8 ± 1.5 18.4 ± 5.6 20.2 ± 1.3 
GSH/GSSG (nmol/mg 
protein) 
16.1 ± 2.4 17.1 ± 4.2 20.6 ± 5.1 17.3 ± 5.4 
 
Data of GSHt, GSSG, and GSH levels, in nmol/mg protein and the GSH/GSSG ratio, are 
expressed as mean ± SD from seven animals in each group. Statistical analysis was made using 
the t-test for the GSHt, GSSG, GSH, and the GSH/GSSG ratio levels in the cerebellum, and GSSG 
and GSH levels in the striatum; the Mann-Whitney Rank Sum test was done for GSHt and the 
GSH/GSSG ratio levels in the striatum. 
 
4.6. MPH treatment increased quinoprotein levels in the 
cerebellum 
 
The quinoprotein levels in the cerebellum, PFC, hippocampus, and striatum are 
represented in Figure 8A, 8B, 8C, and 8D, respectively. Significant differences were found 
in the cerebellum (p = 0.03), since the MPH-treated rats revealed higher levels when were 
compared to the control animals (Figure 8A). Regarding the other three brain areas, no 
differences were found between the two groups (Figure 8B, 8C, and 8D).  
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Figure 8 – Quinoprotein levels in the cerebellum (A), PFC (B), hippocampus (C), and striatum (D) 
of control and MPH-treated rats. Results, in OD/mg protein, are expressed as mean ± SD from 
seven animals in each group. Statistical analysis was made using the t-test (*p < 0.05 treatment vs. 
control). 
 
4.7. Protein carbonylation was not affected by MPH 
treatment in the brain 
 
The protein carbonylation levels were measured in the cerebellum, PFC, 
hippocampus, and striatum are presented in Table 6. No significant differences were 
observed among control and the MPH-treated rats in any of the four areas tested. 
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Table 6 – Protein carbonylation levels in cerebellum, PFC, hippocampus, and striatum of control 
and MPH-treated rats. 
 Protein Carbonylation (% of control) 
Brain Areas Control MPH 
Cerebellum 100 ± 26 103 ± 12 
PFC 100 ± 18 93 ± 15 
Hippocampus 100 ± 20 79 ± 19  
Striatum 100 ± 26 111 ± 34 
 
Results, in percent of control, are expressed as mean ± SD from seven animals in each group. 
Statistical analysis was made using the t-test. 
 
4.8. ATP levels in the peripheral organs remained 
unchanged following MPH treatment 
 
The ATP levels determined in the liver, heart, and kidneys showed no significant 
differences among the two studied groups, as can be seen in Table 7.  
 
Table 7 – ATP levels in the liver, heart, and kidneys of control and MPH-treated rats. 
 ATP (nmol/mg protein) 
Organ Control MPH 
Liver 1.39 ± 1.20 1.74 ± 0.91 
Heart 3.39 ± 2.01 2.19 ± 1.17 
Kidneys 2.34 ± 1.36 1.33 ± 0.78 
 
Results, in nmol ATP/mg protein, are expressed as mean ± SD from seven animals in each group. 
Statistical analysis was made using the t-test for the ATP levels in the liver and heart, and the 
Mann-Whitney Rank Sum test for the ATP values in the kidneys. 
 
4.9. MPH treatment reduced GSSG levels in the heart 
 
The redox status was evaluated in the heart and it is represented in Figure 9. As 
can be seen, GSSG levels were decreased (p = 0.049), GSH levels were increased (p = 
0.04), and GSH/GSSG ratio was increased (p = 0.04). Regarding the GSHt levels, no 
significant differences were found among the two groups.  
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Figure 9 – Levels of GSHt (A), GSSG (B), GSH (C), and GSH/GSSG ratio (D) in the heart of 
control and MPH-treated rats. Results, in nmol/mg protein or in GSH/GSSG ratio, are expressed as 
mean ± SD from seven animals in each group. Statistical analysis was made using the t-test for 
GSHt, GSSG and GSH levels, and the Mann-Whitney Rank Sum test for the GSH/GSSG ratio 
levels (
*
p<0.05 vs. control). 
 
The levels of GSHt, GSSG, GSH, and GSH/GSSG ratio in the other two peripheral 
organs, liver and kidneys, are represented in Table 8. No significant differences among 
treated groups in either of the four parameters were observed in the liver or kidneys of the 
adolescent rats. 
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Table 8 – Glutathione parameters in the liver and kidneys of control and MPH-treated rats. 
 Liver Kidneys 
Parameter Control MPH Control MPH 
GSHt (nmol/mg 
protein) 
32.4 ± 3.9 33.3 ± 7.8 1.9 ± 0.9 2.1 ± 0.9 
GSSG (nmol/mg 
protein) 
5.2 ± 1.1 6.2 ± 1.4 0.2 ± 0.1 0.2 ± 1.1 
GSH (nmol/mg 
protein) 
21.9 ± 3.3 20.8 ± 5.9 1.6 ± 0.8 1.7 ± 0.8 
GSH/GSSG (nmol/mg 
protein) 
4.3 ± 1.0 3.4 ± 1.0 10.3 ± 2.8 9.1 ± 4.3 
 
Data of GSHt, GSSG, and GSH levels, in nmol/mg protein or in GSH/GSSG ratio, are expressed 
as mean ± SD from seven animals in each group. Statistical analysis was made using the t-test for 
the GSHt, GSSG, GSH, and the GSH/GSSG ratio levels in the liver, and GSSG and the 
GSH/GSSG ratio levels in the kidneys. The Mann-Whitney Rank Sum test was used for the 
analysis of the GSHt and GSH levels in the kidneys. 
  
4.10. Quinoprotein levels in the peripheral organs were not 
altered by MPH treatment 
 
 In Table 9 are represented the results of the quinoprotein levels in the liver, heart, 
and kidneys of adolescent rats after the exposure to 5 mg/kg of MPH or 5% sucrose for 
seven days. No significant differences were found in any of the peripheral organs. 
 
Table 9 – Quinoproteins levels in the liver, heart, and kidneys of control and MPH-treated rats. 
 Quinoproteins (OD/mg protein) 
Organ Control MPH 
Liver 0.14 ± 0.01 0.15 ± 0.01 
Heart 0.28 ± 0.02 0.27 ± 0.02 
Kidneys 0.21 ± 0.04 0.18 ± 0.03 
 
Results, in OD/mg protein, are expressed as mean ± SD from seven animals in each group. 
Statistical analysis was made using the t-test for the quinoprotein levels in the heart, and the Mann-
Whitney Rank Sum test for the statistical analysis of the quinoprotein levels in the liver and 
kidneys. 
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4.11. Protein carbonylation levels in the peripheral organs 
remained unaltered following MPH treatment 
 
 Protein carbonylation levels in the liver, heart, and kidneys after the experimental 
protocol are presented in Table 10. No significant differences were observed in MPH-
treated group when compared to the control group.  
 
Table 10 – Protein carbonylation levels in the liver, heart, and kidneys of control and MPH-treated 
rats. 
 Protein Carbonylation (% of control) 
Organ Control MPH 
Liver 100 ± 19 118 ± 29 
Heart 100 ± 36 86 ± 7 
Kidneys 100 ± 36 104 ± 35 
 
Results, in percent of control, of seven animals in each group are expressed as mean ± SD. 
Statistical analysis was made using the t-test for the levels of protein carbonylation in the heart, 
and the Mann-Whitney Rank Sum test for the levels of protein carbonylation in the liver and 
kidneys. 
   
4.12. MPH promoted tissue changes in the peripheral 
organs, mainly promoting damage to the heart and 
kidneys 
 
The qualitative histologic examination of peripheral organs (liver, heart, and 
kidneys) of control and MPH-treated rats was done using the haematoxylin and eosin 
staining (Figures 10, 11, and 12). 
The liver of control animals showed a normal histological structure although a 
slight hepatocytes vacuolization surrounding the portal spaces was observed (Figure 10B 
and 10D). In MPH-treated rats, the hepatic structure was also preserved, however a 
moderate blood congestion and a more pronounced hepatocyte vacuolization in the 
periportal areas comparatively to controls was observed (Figure 10B and 10D). No 
necrotic zones or interstitial inflammatory cell infiltration was observed in either groups.  
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A B 
D C 
 
Figure 10 – Representative photomicrographs of liver sections stained with hematoxylin/eosin from 
control (A, C) and MPH-treated rats (B, D). A and C depict a normal histological structure, although 
with a slight micro vesicular vacuolization affecting the hepatocytes nearby the portal spaces (white 
arrows). However, this hepatocyte vacuolization was more notorious in MPH-treated animals (white 
arrows) as depicted in B and D; sign of blood congestion (yellow arrows) can also be observed in 
B. 
 
In the heart, the control group showed a preserved tissue structure (Figure 11A 
and 11C). The MPH-treated animals showed an increase of the interstitial space, 
suggestive of oedema, with focal deposition of fibrin-like material, which were 
accompained by an intense vascular congestion (Figure 11B and 11D). 
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Figure 11 – Representative photomicrographs of heart sections from control (A, C) and MPH-
treated rats (B, D) stained with hematoxylin and eosin. A and C show a normal histological 
structure. Signs of vascular congestion, with enlarged blood vessels filled with erythrocytes are 
depicted in B (blue arrows); in D, a general enlargement of interstitial space with focal deposition of 
fibrin-like material (yellow arrows) is observed; some cardiomyocytes with cytoplasmic 
vacuolization are also observed in D (white arrows).  
 
The renal tissue organization remained well-maintained in the control group 
(Figure 12A and 12C). However, the MPH-treated group presented intense cellular 
damage, mainly affecting the proximal tubules, with cellular vacuolization, pyknotic nuclei, 
necrotic areas and leucocyte infiltrations (Figure 12B and 12D). Moreover, the glomeruli of 
these animals showed reduced Bowman’s space with cellular infiltrations nearby the 
Bowman’s capsule. The wall of the renal arteries was thicker in the MPH-treated animals 
with an apparent proliferation of smooth muscle cells (Figure 12B and 12D). 
 
 
A B 
D C 
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Figure 12 – Representative photomicrographs of kidney sections from control (A) and MPH-treated 
rats (B, C, D) stained with the hematoxylin and eosin. The renal structure was histologically 
preserved in A. Extensive necrotic zones with tissue disorganization and cellular infiltration (white 
arrows) as well as abundant sign of cellular vacuolization, mainly affecting the proximal tubes 
(yellow arrows), are depicted in B, C, and D. The greater thickness of arteriolar walls with an 
apparent proliferation of smooth muscle cells nearby the glomerulus (green arrows) and the 
reduction of Bowman’s space are also depicted in C. 
 
4.13. MPH treatment did not cause changes in fibrous tissue 
in the peripheral organs  
 
The assessment of fibrous tissue in the liver, heart, and kidneys of both control 
and MPH-treated animals was done by the Picrosirius Red technique, which stains 
collagen red and muscle tissue yellow. The results are presented in Table 11 and no 
significant differences were observed among studied groups in the percentage of 
collagen/muscle area of the peripheral organs tested. 
A B 
C D 
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Table 11 – Collagen detection in the liver, heart, and kidneys of control and MPH-treated rats. 
 Collagen (% collagen/muscle area) 
Organ Control MPH 
Liver 0.80 ± 0.42 1.32 ± 0.69 
Heart 1.98 ± 0.53 1.90 ± 0.44 
Kidneys 2.04 ± 0.44 2.03 ± 0.45 
 
Results, in percent collagen/muscle area, are expressed as mean ± SD from four animals in each 
group. Statistical analysis was made using the Mann-Whitney Rank Sum test. 
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5. Discussion and Conclusions 
 
MPH is the primary stimulant prescribed for the treatment of ADHD; however, its 
increasing use and abuse during critical stages of neurodevelopment in children and 
adolescents, has raised great concerns about possible consequences to the long-term 
exposure to MPH. Although preclinical studies in laboratory animals have been conducted 
over the years, the vast majority does not have into account two major factors with clinical 
relevance: the use of pharmacologically relevant doses and the route of administration. 
Clinical use of MPH typically involves oral administration of relatively low doses, whereas, 
the majority of the studies tend to use high doses, generally administrated via i.v., i.p., or 
subcutaneously. Moreover, some studies use adult animals, while the MPH use begins 
mainly in childhood. Therefore, in the present study, we studied the effects of a clinical 
MPH dose scheme (2 x 5 mg/kg, 5h apart, oral route) in an adolescent rat model for 
seven days. A brief discussion of the major findings follows.  
 
5.1. MPH did not promote temperature, weight or 
food/water intake changes  
Hyperthermia is one of the most lifethreatening effects among stimulant drugs. The 
increase of the CNS metabolic activity can lead to a dysregulation between heat 
production and dissipation with the drug use (Carvalho et al., 2012). In fact, 3,4-
methylenedioxymethamphetamine (MDMA), an amphetamine derivate commonly used in 
recreational scenarios, is one of the most studied amphetamine regarding its hyperthermic 
effects, since elevated body temperature after exposure to this drug has been reported in 
both animals and humans following similar conditions of exposure (i.e., same dose 
scheme and route of administration) (Carvalho et al., 2012, Teixeira-Gomes et al., 2016). 
Since MPH is also a stimulant with a similar pharmacology to AMPH, the body 
temperature of the rats in several time-points throughout the experimental period was 
measured. However, no significant differences were found between control and MPH-
treated groups. This result contrasts to early findings where a significant hyperthermia 
(41.5ºC) was reported 2 h after the fourth injection of MPH (4 x 22 mg/kg, every 2 h, i.p.) 
in male Sprague Dawley rats with PND 83 to 87 by Levi and coworkers (Levi et al., 2012). 
In the same study, they also concluded that the threshold dose of MPH necessary to 
significantly raise the body temperature in rats was 10-fold higher than the one necessary 
for AMPH exposure. Accordingly, hyperthermia is somewhat less expected to happen 
after overdoses of MPH than with AMPH (Levi et al., 2012).  In fact, hyperthermia is a rare 
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acute effect that has been reported only after severe intoxications of MPH and not after 
ingestion of therapeutic doses (Scharman et al., 2007, Peyre and Delorme, 2012). 
Therefore, our low dose scheme, comparable to the human situation, can explain why the 
body temperature of adolescent rats was not changed by MPH treatment. 
In addition to hyperthermia, we also evaluated body weight gain and food/water 
intake in adolescent rats during the seven days treatment. In the literature, significant 
differences were found in appetite, food intake, and, consequently, in weight gain in 
rodents and humans treated with MPH (Rapport and Moffitt, 2002, Gray et al., 2007, Alam 
and Najam, 2015, Thanos et al., 2015). A tendency for decrease in body weight gain was 
found in the MPH-treated group in our study, though not statistically significant. The same 
tendency was also reported by Alam and Najam. After the oral administration of MPH 
twice a day (5mg/kg/day) for 4 weeks, a tendency for weight loss in the third week was 
observed (Alam and Najam, 2015). Significant decreases were also found with a lower (2 
mg/kg/day) and a higher dose (8 mg/kg/day) in the same regime, which relates the long-
term administration to the consequent weight loss (Alam and Najam, 2015). In another 
study, the weight loss was also reported after rats aged 4 weeks received a dual dosage 
of 4 mg/kg and 10 mg/kg or 30 mg/kg and 60 mg/kg of MPH administered in daily drinking 
water for three months. The lower dose was administrated in the first hour and the higher 
dose was administrated for seven hours (Thanos et al., 2015). These previous two studies 
used either higher doses and/or longer times of drug treatment, which may explain the 
different findings in weight gain to our study. Regarding the food and water intake, the 
published data is contradictory. In our study, MPH treatment did not affect both food and 
water intake; however, Alam and Najam reported an increased food and water intake in all 
weeks and at all doses tested (2, 5, or 8 mg/kg/day) (Alam and Najam, 2015). Meanwhile, 
Thanos and coworkers reported a decreased food intake particularly in the first five weeks 
of a three months treatment (Thanos et al., 2015). Overall, our results show that MPH is 
somehow related with weight loss but that loss is not directly related to food/water intake. 
Hence, there is a need to understand the mechanisms underlying this effect since 
decreased appetite, weight loss and anorexia are reported as side effects of MPH in 
humans (Rapport and Moffitt, 2002). 
5.2. MPH induced brain changes regarding energetic 
content, redox status and quinoprotein formation 
The potential neurotoxicity of MPH has raised attention in the last years but there 
are still few studies concerning the effects of a long time exposure to this stimulant and 
the implications to the brain. Thus, we aimed to verify if a pharmacologically relevant MPH 
Part V – Discussion and Conclusions 
69 
 
regimen can cause significant changes in several brain areas, namely regarding ATP 
levels and oxidative stress. 
In our study, no differences were found in the ATP levels in the cerebellum, 
hippocampus, and striatum of the MPH-treated adolescent rats; however, data showed a 
strong tendency for a decrease in ATP levels in the PFC. Interestingly, also in PND 40 
Wistar rats, our group found a significant decrease in the ATP content of the frontal cortex 
following three MDMA doses (each dose 5 mg/kg, i.p., every 2 h), but not in the 
cerebellum, hippocampus, and striatum (Teixeira-Gomes et al., 2016). To the best of our 
knowledge, no previous studies in vivo evaluated this parameter after MPH exposure. 
Published data for MPH focused on the activity of the mitochondrial respiratory chain 
(Fagundes et al., 2010a) and the activity of enzymes involved in the Krebs cycle (Reus et 
al., 2013). A study with young Wistar rats (PND 25), which received a single injection of 
MPH (1, 2 or 10 mg/kg, via i.p.) or an injection once a day for 28 days, showed a 
reduction in the activity of complex I in the cerebellum and PFC after the acute treatment, 
and an increase in the activities of complexes II and IV after the chronic treatment 
(Fagundes et al., 2010a). Another study reported a decrease activity on citrate synthase 
and isocitrate dehydrogenase in the cerebellum, striatum, PFC, hippocampus, and cortex 
after young Wistar rats (PND 25) received MPH (1.0, 2.0 or 10 mg/kg, via i.p.) during 28 
days, while, after a single injection, the activity of both enzymes was not altered in any of 
the brain areas studied (Reus et al., 2013). Of note, mitochondria generate most of the 
energy of the brain by converting oxygen and nutrients into ATP, so, if any abnormality is 
detected in these organelles, the neuronal function and survival can be affected since 
ATP is critical for the correct functioning of the brain (Barbosa et al., 2015). When 
comparing the studies previously done with our results, it can be seen that the animals’ 
age, the dosage regimen, the time of exposure, and the route of administration are 
important factors regarding the energetic impairment in the brain after MPH exposure. 
Still, our work raises the question about the ATP levels in the brain of adolescent rats after 
a dose scheme that reproduces the human scenario, and, it is possible to speculate that 
MPH may promote energetic impairment in the cortex, as did MDMA in animals with the 
same age. A more profound investigation is needed to better understand this 
phenomenon. 
The assessment of oxidative stress in the brain after exposure to MPH was also 
done. Earlier evidence already reported increased lipid peroxidation in several brain areas 
after different MPH dose schemes (Martins et al., 2006, Schmitz et al., 2012, 
Motaghinejad et al., 2016). Additionally, it is known that oxidative stress plays an 
important role in amphetamines neurotoxicity (Carvalho et al., 2012), so, since MPH is 
equally a stimulant, we determined oxidative stress parameters like the glutathione levels, 
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quinoprotein formation, and protein carbonylation in the cerebellum, PFC, hippocampus, 
and striatum of adolescent rats exposed for one week to MPH. 
Our findings showed that MPH treatment increased the antioxidant status of the 
PFC and hippocampus, as this work found increased GSH/GSSG ratio in the PFC and in 
the hippocampus, whereas decreased GSSG levels in the later area. No differences were 
found in the glutathione levels in the cerebellum and striatum. To the best of our 
knowledge, this was the first report of the glutathione status in adolescent rats after one-
week exposure to MPH (2 x 5 mg/kg, 5 h apart, oral route). Of note, GSH is the most 
important cellular antioxidant and it is critical for the detoxification of xenobiotics and their 
metabolites and to maintain the intracellular redox balance (Owen and Butterfield, 2010). 
Under normal conditions, GSH is the most prevalent form, however, under oxidative 
stress, GSSG levels increase, so, the GSH/GSSG ratio has been used as an index of 
oxidative stress (Costa et al., 2011).  In our study, the GSH/GSSG ratio increased in the 
PFC and the hippocampus, so, this is the first experimental demonstration that MPH 
reduces oxidative stress in the brain of adolescent rats after the administration of 
therapeutic relevant doses. Recently, a preclinical study reported a dose-dependent 
increase of GSSG content and a reduction of GSH content in the hippocampus of Wistar 
rats with 8 weeks old after chronic treatment (21 days) with high doses of MPH (2.0, 5.0, 
10, or 20 mg/kg, via i.p.) (Motaghinejad et al., 2016). However, the age of the animals and 
the duration of the protocol seem the most relevant differences to explain that induced 
oxidative stress.  
Regarding the protein-bound quinone formation, a significant increase in the 
cerebellum was observed in the MPH-treated group. No differences were observed in the 
other brain areas evaluated. Once again, no previous studies were found that evaluate 
this parameter after MPH administration. Nevertheless, quinones can promote the 
formation of ROS and, consequently, induce severe oxidative stress. ROS can bind to 
macromolecules like lipids, proteins, and DNA (Bolton et al., 2000). It remains to be 
clarified why the cerebellum is the only brain area affected.  
Another oxidative stress parameter evaluated was the protein carbonylation, an 
irreversible oxidative damage marker to proteins associated to a permanent loss of 
cellular function that can lead to tissue damage (Dalle-Donne et al., 2006). Briefly, 
carbonyl groups are formed in proteins by the reaction of ROS and the protein or by direct 
oxidation of proteins by ROS. If the carbonylated proteins are not degraded, their 
accumulation leads to cell and tissue injury (Dalle-Donne et al., 2006). Recently, studies 
showed that MPH induces the protein carbonyl formation in specific brain areas (Martins 
et al., 2006, Comim et al., 2014). Martins and coworkers reported a dose-dependent 
increase on protein carbonylation in the cerebellum, PFC, hippocampus, and striatum of 
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young (PND 25) and adult Wistar rats (PND 60) after i.p. injections of MPH (1.0, 2.0, or 10 
mg/kg), once daily, during 28 days (Martins et al., 2006). Another study reported protein 
damage in the cerebellum and hippocampus of adult SHR rats (PND 60) after chronic 
exposure to MPH (2 mg/kg, via i.p., once daily) during 28 days (Comim et al., 2014). In 
our study, no significant differences were observed between the groups in any of the four 
areas tested. When comparing the studies, it can be seen that they differ in several 
factors that have impact in the pharmokinetic profile of MPH and, consequently, in the 
results. Among the factors, we highlight the animals’ age, the animal model (Wistar rat vs. 
SHR rat, the animal model of ADHD), the dosage regimen and long treatment period, and 
the i.p. route of administration. Overall, it became demonstrated that MPH was not able to 
increase protein carbonylation in the brain of adolescent rats after one-week exposure to 
a pharmacological relevant oral dose. 
 
5.3. MPH induced organs-related changes regarding redox 
status and cellular damage 
Case reports of liver, heart, and kidneys injuries attributed to MPH are found in the 
literature but there are very few studies in animals. Therefore, it is of extreme importance 
to investigate the effects of MPH on peripheral organs of adolescent animals and try to 
understand if therapeutic doses could promote any histological or functional adverse 
effect as it was done in the present work. 
As biomarkers of liver or heart integrity, plasma ALT, AST, CK-MB and total-CK 
were measured and no differences were found between the control and the MPH-treated 
group.   
When we evaluated the ATP levels, no differences were found in the liver, heart, or 
kidneys of MPH-treated rats when compared to the control group. In the literature, no in 
vivo or in vitro studies reporting the ATP levels in the peripheral organs of laboratory 
animals after MPH exposure were found. Thus, to the best of our knowledge, our work 
gives the first hint that therapeutic doses of MPH do not impair the energetic content of 
the peripheral organs evaluated. 
Regarding the oxidative stress parameters, a reduction of the GSSG levels, an 
increase of the GSH levels, and, consequently, an increase of the GSH/GSSG ratio were 
observed only in the heart. As mentioned above, the GSH/GSSG ratio is as an index of 
oxidative stress and, since an increase of this ratio was observed in the heart, we can 
speculate that MPH increases the cardiac antioxidant status. No differences were 
observed in the glutathione levels of the liver and the kidneys following MPH treatment. 
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Additionally, the peripheral organs did not presented any alteration in the other two 
oxidative stress parameters evaluated, quinoprotein levels and protein carbonylation. To 
the best of our knowledge, the oxidative stress was, for the first time, evaluated in the 
peripheral organs of adolescent rats exposed to MPH. Altogether, these results indicate 
that oxidative stress does not occur in the peripheral organs of adolescent rat following 
therapeutic oral doses of MPH. Moreover, therapeutic oral doses might even provide 
protection to the heart against oxidative stress, according to our data.  
The histological examination of each peripheral organ provided us more 
information about the possible toxic effect of MPH. In the liver of MPH-treated rats, we 
found signals of blood congestion and a more pronounced hepatocyte vacuolization in the 
periportal areas. No necrotic zones or interstitial inflammatory cell infiltration was 
observed in either group. While MPH did not induced any significant hepatotoxicity under 
our experimental protocol, another study reported hepatocellular necrosis 24 h after an i.v. 
administration of MPH (100 mg/kg) to ICR male mice (Roberts et al., 1994), which 
corroborates the reported liver injury due i.v. abuse of MPH in humans (Mehta et al., 
1984, Stecyk et al., 1985). However, the dose described in that study (100 mg/kg) is very 
high and might correspond to an abuse scenario, unlike our oral dose scheme that 
corresponds to a clinical setting. 
In the heart, a general enlargement of the interstitial space with focal deposition of 
fibrin-like material and an intense vascular congestion was observed. As previously 
mentioned in section 1.4.2.1., pronounced lesions in the myocardium were associated to 
MPH administration in two laboratory animals models after a different dose regimen (1) 
Swiss-Webster mice received 2.5 or 5.0 mg/kg of MPH, three times a week, i.p., or, 5.0 
mg/kg, once a day, via oral, during 4 or 14 weeks; (2) Sprague Dawley rats received 2.0, 
20, or 100 mg/kg of MPH, via i.p., for periods of 3, 6, or 9 weeks (Henderson and Fischer, 
1995). Additionally, myofibril structure disruption related with mitochondria degeneration 
was found after oral administration of MPH (5.0, 10, or 20 mg/kg) to PND 25 Wistar rats 
for 5 days/week during three months (Take et al., 2008). Although the animals’ age, the 
dose regimen, the administration route, and the time of exposure were different in the 
three studies, MPH has the potential to damage the heart even after therapeutic doses 
given to adolescent rats. These data corroborate the cardiotoxic events attributed to this 
stimulant in humans either after long-term treatment with therapeutic doses or following 
overdoses (Lucas et al., 1986, Daly et al., 2008, Nymark et al., 2008, Thompson and 
Thompson, 2010, Munk et al., 2015). Regarding the mechanism behind these 
cardiotoxicity, more studies are required, but oxidative stress should be not involved. In 
fact, an increase in the antioxidant status of the heart was found. Possibly, vascular 
changes promoted by MPH can be the missing link. 
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Regarding the renal tissue, the MPH-treated group presented extensive necrotic 
zones, cellular infiltration, and cellular vacuolization mainly affecting the proximal tubes. It 
was only possible to find one other study focused on the possible renal effects of MPH by 
performing both in vivo and in vitro assays (Salviano et al., 2015). Twenty-four hours after 
oral administration of MPH (10 mg/kg) to adult male Wistar rats, the kidneys of both 
control and treated groups showed a preserved tissue structure. Despite this, in vitro 
studies showed that the addition of 10 µg/ml of MPH to the isolated rat kidney significantly 
reduced the glomerular filtration rate, the urine flow, and the sodium transport (Salviano et 
al., 2015). MPH may have a nephrotoxic effect depending on the time of exposure, but 
more studies have to be made to better understand what mechanisms are implied in the 
MPH-induced injury kidney. However, it seems clear that oxidative stress does not play a 
role in these toxic events to the kidney, since no differences were found in oxidative stress 
parameters in this organ.  
The histological examination corroborates the results obtained by the plasma ALT, 
AST, CK-MB, and total-CK since there were no signs of necrosis in any of the peripheral 
organs. Additionally, the conjunctive tissue ratio was also assessed in our study, as 
putative index of drug-induced injury. Briefly, an accumulation of conjunctive tissue leads 
to fibrosis, and may be the result of stimuli like drug exposure, persistent infections, and 
autoimmune reactions (Wynn, 2008). The fibrotic cascade is mediated by complex 
biological processes and, as it progresses, impairments in the tissue architecture and 
function and, eventually, organ failure can occur (Ueha et al., 2012). In our work, the 
amount of fibrous tissue was not altered by MPH treatment. Despite this, we found that 
MPH may induce heart and kidneys injuries in adolescent rats, but it seems that vascular 
responses promoted by MPH might be the determinants for that injury since fibrosis is the 
end result of chronic inflammation and was not verified in our study (Wynn, 2008, Ueha et 
al., 2012). Importantly, our exposure period to MPH was possibly short, unabling this kind 
of damage to occur. So, more studies are necessary to confirm if MPH induces fibrosis in 
peripheral organs. 
 
5.4. Conclusions 
 
The worldwide rise in ADHD diagnosis and, consequently, the widespread 
prescription of MPH has raised substantial debates regarding the long-term effects 
resulting from an early exposure to this drug. In this dissertation, we showed that MPH 
increased the GSH/GSSG ratio in the PFC and hippocampus, which suggests that, at 
therapeutic doses orally administrated to adolescent rats, this drug increases antioxidant 
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defenses and might have a protective role in these two brain areas. On the other hand, 
MPH exposure in adolescent rats did not promote any significant changes in ATP content 
or protein carbonylation in the brain areas, but, significantly increased the quinoprotein 
levels in the cerebellum. Regarding the peripheral organs, the MPH dose scheme used 
did not alter the ATP, quinoprotein, or protein carbonylation levels in any of the organs 
studied. However, once again, MPH showed a protective role in the heart of MPH-treated 
rats, since the GSSG levels were significantly reduced in this organ. Interestingly, MPH 
compromised the normal tissue organization mainly in the heart and kidneys without 
promoting any changes in the plasma biomarkers of liver or heart integrity and in the 
amount of fibrous tissue.  
This study showed for the first time that therapeutic oral doses of MPH are might 
have a beneficial role in the levels of glutathione in adolescent rats in the brain and heart, 
though they might promote several tissue morphologic changes, mainly vascular related 
changes, in the heart and kidney. Thus, further investigation is needed in order to 
understand the mechanisms behind these alterations and what factors can promote them. 
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